BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Dusheiko G. Side effects of alpha interferon in chronic hepatitis C. Hepatology 1997;26:112S-21S. [PMID: 9305675 DOI: 10.1002/hep.510260720] [Cited by in Crossref: 279] [Cited by in F6Publishing: 252] [Article Influence: 10.7] [Reference Citation Analysis]
Number Citing Articles
1 Liu BQ, Liu RB, Li WP, Mao XT, Li YN, Huang T, Wang HL, Chen HT, Zhong JY, Yang B, Chai RJ, Cao Q, Jin J, Li YY. XAF1 prevents hyperproduction of type I interferon upon viral infection by targeting IRF7. EMBO Rep 2023;24:e55387. [PMID: 36394357 DOI: 10.15252/embr.202255387] [Reference Citation Analysis]
2 Wu C, Lin C, Chen H, Chang SC, Chang M, Lin K. Lanostane triterpenoids from the medicinal mushroom Ganoderma tsugae. Phytochemistry Letters 2022;51:114-8. [DOI: 10.1016/j.phytol.2022.08.002] [Reference Citation Analysis]
3 Da BL. Clinical trials in hepatitis D virus: Measuring success. Hepatology 2022. [PMID: 35969089 DOI: 10.1002/hep.32732] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Hagag RS, Fakhry MM, Ahmed OA, Abdalgeleel SA, Radwan MA, Naguib GG. Assessment of efficacy and safety of two Egyptian protocols for treatment-experienced HCV patients: an observational study. Egypt J Intern Med 2022;34. [DOI: 10.1186/s43162-022-00126-8] [Reference Citation Analysis]
5 Trifan A, Stratina E, Rotaru A, Stafie R, Zenovia S, Nastasa R, Huiban L, Sfarti C, Cojocariu C, Cuciureanu T, Muzica C, Chiriac S, Girleanu I, Singeap A, Stanciu C. Changes in Liver Steatosis Using Controlled Attenuation Parameter among Patients with Chronic Hepatitis C Infection Treated with Direct-Acting Antivirals Therapy Who Achieved Sustained Virological Response. Diagnostics 2022;12:702. [DOI: 10.3390/diagnostics12030702] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
6 Harney BL, Whitton B, Paige E, Brereton R, Weiss R, Membrey D, Wade AJ, Iser D, Kemp W, Roberts SK, Spelman T, Sacks-Davis R, Hellard ME, Doyle JS. A multi-site, nurse-coordinated hepatitis C model of care in primary care and community services in Melbourne, Australia. Liver Int 2022;42:522-31. [PMID: 34821021 DOI: 10.1111/liv.15107] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Manchukonda B, Kumar AH. Network profiling of hepatocellular carcinoma targets for evidence based pharmacological approach to improve clinical efficacy.. [DOI: 10.1101/2022.02.21.481313] [Reference Citation Analysis]
8 Lagreca LCC, Parise ER, Farias JLRD, Corvaro C, Azevedo MFD. Avaliação audiológica em pacientes com hepatite C crônica tratados por antivirais de ação direta. Audiol , Commun Res 2022;27. [DOI: 10.1590/2317-6431-2021-2548] [Reference Citation Analysis]
9 Matveev AV, Egorova EA, Koryanova KN, Bekirova EY, Suleymanova NL. Safety of Interferon Products: a Retrospective Analysis of Adverse Reactions Spontaneously Reported in the Republic of Crimea. jour 2021;3. [DOI: 10.36107/hfb.2021.i3.s117] [Reference Citation Analysis]
10 Hasan LK, Deadwiler B, Haratian A, Bolia IK, Weber AE, Petrigliano FA. Effects of COVID-19 on the Musculoskeletal System: Clinician's Guide. Orthop Res Rev 2021;13:141-50. [PMID: 34584465 DOI: 10.2147/ORR.S321884] [Cited by in Crossref: 5] [Cited by in F6Publishing: 9] [Article Influence: 2.5] [Reference Citation Analysis]
11 Müller S, Bieber T, Ständer S. Therapeutic potential of biologics in prurigo nodularis. Expert Opin Biol Ther 2021;:1-12. [PMID: 34289753 DOI: 10.1080/14712598.2021.1958777] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
12 Shao YY, Cheng AL, Hsu CH. An Underdiagnosed Hypothyroidism and Its Clinical Significance in Patients with Advanced Hepatocellular Carcinoma. Oncologist 2021;26:422-6. [PMID: 33687750 DOI: 10.1002/onco.13755] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
13 Zang R, Case JB, Yutuc E, Ma X, Shen S, Gomez Castro MF, Liu Z, Zeng Q, Zhao H, Son J, Rothlauf PW, Kreutzberger AJB, Hou G, Zhang H, Bose S, Wang X, Vahey MD, Mani K, Griffiths WJ, Kirchhausen T, Fremont DH, Guo H, Diwan A, Wang Y, Diamond MS, Whelan SPJ, Ding S. Cholesterol 25-hydroxylase suppresses SARS-CoV-2 replication by blocking membrane fusion. Proc Natl Acad Sci U S A 2020;117:32105-13. [PMID: 33239446 DOI: 10.1073/pnas.2012197117] [Cited by in Crossref: 107] [Cited by in F6Publishing: 121] [Article Influence: 35.7] [Reference Citation Analysis]
14 Perico L, Benigni A, Casiraghi F, Ng LFP, Renia L, Remuzzi G. Immunity, endothelial injury and complement-induced coagulopathy in COVID-19. Nat Rev Nephrol. 2021;17:46-64. [PMID: 33077917 DOI: 10.1038/s41581-020-00357-4] [Cited by in Crossref: 263] [Cited by in F6Publishing: 282] [Article Influence: 87.7] [Reference Citation Analysis]
15 Allahverdiyeva S, Keskin E, Pınar PT, Yunusoğlu O, Yardım Y, Şentürk Z. Electroanalytical investigation and determination of hepatitis C antiviral drug ledipasvir at a non-modified boron-doped diamond electrode. Diamond and Related Materials 2020;108:107962. [DOI: 10.1016/j.diamond.2020.107962] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 5.0] [Reference Citation Analysis]
16 Hao SR, Yan R, Zhang SY, Lian JS, Cai H, Zhang XL, Zheng L, Jia HY, Hu JH, Yu GD, Gu JQ, Ye CY, Jin CL, Lu YF, Xin JJ, Sheng JF, Yang YD. Interferon-α2b spray inhalation did not shorten virus shedding time of SARS-CoV-2 in hospitalized patients: a preliminary matched case-control study. J Zhejiang Univ Sci B 2020;21:628-36. [PMID: 32748578 DOI: 10.1631/jzus.B2000211] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
17 Serumondo J, Penkunas MJ, Niyikora J, Ngwije A, Kiromera A, Musabeyezu E, Umutesi J, Umuraza S, Musengimana G, Nsanzimana S. Patient and healthcare provider experiences of hepatitis C treatment with direct-acting antivirals in Rwanda: a qualitative exploration of barriers and facilitators. BMC Public Health 2020;20:946. [PMID: 32546216 DOI: 10.1186/s12889-020-09000-0] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
18 Sise ME, Strohbehn IA, Bethea E, Gustafson JL, Chung RT. Balancing the risk and rewards of utilizing organs from hepatitis C viremic donors. Curr Opin Organ Transplant 2019;24:351-7. [PMID: 31090648 DOI: 10.1097/MOT.0000000000000651] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
19 Abd Elaziz MS, Nada ASE, ElSayed SH, Nasr GS, Zaky AG. Ocular comorbidities with direct-acting antiviral treatment for chronic hepatitis C virus (HCV) patients. Int Ophthalmol 2020;40:1245-51. [PMID: 31965393 DOI: 10.1007/s10792-020-01290-y] [Reference Citation Analysis]
20 Martha SR, Cheng Q, Fraser JF, Gong L, Collier LA, Davis SM, Lukins D, Alhajeri A, Grupke S, Pennypacker KR. Expression of Cytokines and Chemokines as Predictors of Stroke Outcomes in Acute Ischemic Stroke. Front Neurol 2019;10:1391. [PMID: 32010048 DOI: 10.3389/fneur.2019.01391] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 5.0] [Reference Citation Analysis]
21 Chang CP, Su YC, Lin MC, Huang ST. Chinese Herbal Medicine Ameliorated the Development of Chronic Kidney Disease in Patients with Chronic Hepatitis C: A Retrospective Population-Based Cohort Study. Evid Based Complement Alternat Med 2019;2019:5319456. [PMID: 31871483 DOI: 10.1155/2019/5319456] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
22 Taft J, Bogunovic D. The Goldilocks Zone of Type I IFNs: Lessons from Human Genetics. J Immunol 2018;201:3479-85. [PMID: 30530500 DOI: 10.4049/jimmunol.1800764] [Cited by in Crossref: 21] [Cited by in F6Publishing: 23] [Article Influence: 5.3] [Reference Citation Analysis]
23 Gull I, Aslam MS, Tipu I, Mushtaq R, Ali TZ, Athar MA. Development of latent Interferon alpha 2b as a safe therapeutic for treatment of Hepatitis C virus infection. Sci Rep 2019;9:10867. [PMID: 31350425 DOI: 10.1038/s41598-019-47074-y] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
24 de Wilde AH, Snijder EJ, Kikkert M, van Hemert MJ. Host Factors in Coronavirus Replication. Curr Top Microbiol Immunol. 2018;419:1-42. [PMID: 28643204 DOI: 10.1007/82_2017_25] [Cited by in Crossref: 160] [Cited by in F6Publishing: 144] [Article Influence: 40.0] [Reference Citation Analysis]
25 Lapumnuaypol K, Thongprayoon C, Wijarnpreecha K, Cheungpasitporn W. Impact of hepatitis C sustained viral response on cardiovascular diseases: a meta-analysis. Hosp Pract (1995). 2019;47:105-110. [PMID: 31018721 DOI: 10.1080/21548331.2019.1612066] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
26 Su KP, Lai HC, Peng CY, Su WP, Chang JP, Pariante CM. Interferon-alpha-induced depression: Comparisons between early- and late-onset subgroups and with patients with major depressive disorder. Brain Behav Immun 2019;80:512-8. [PMID: 31059806 DOI: 10.1016/j.bbi.2019.04.032] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 6.8] [Reference Citation Analysis]
27 Atta NF, Galal A, Ahmed YM. New strategy for determination of anti-viral drugs based on highly conductive layered composite of MnO2/graphene/ionic liquid crystal/carbon nanotubes. Journal of Electroanalytical Chemistry 2019;838:107-18. [DOI: 10.1016/j.jelechem.2019.02.056] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 4.5] [Reference Citation Analysis]
28 Elgouhary SM, Said-Ahmed KE, Mowafy MA. Anatomical and Functional Retinal Complications of Combined Sofosbuvir and Ribavirin Therapy in Patients With Chronic Hepatitis C Virus. Ophthalmic Surg Lasers Imaging Retina 2019;50:39-41. [PMID: 30640394 DOI: 10.3928/23258160-20181212-06] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
29 Pan CQ, Tiongson BC, Hu KQ, Han SB, Tong M, Chu D, Park J, Lee TP, Bhamidimarri KR, Ma X, Xiao PY, Mohanty SR, Wang D. Real-World Study on Sofosbuvir-based Therapies in Asian Americans With Chronic Hepatitis C. J Clin Gastroenterol 2019;53:147-54. [PMID: 29912759 DOI: 10.1097/MCG.0000000000001078] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
30 Borkar DS, Butler NJ. Interferons and Intravenous Immunoglobulin. Treatment of Non-infectious Uveitis 2019. [DOI: 10.1007/978-3-030-22827-9_10] [Reference Citation Analysis]
31 Manickam C, Shah SV, Lucar O, Ram DR, Reeves RK. Cytokine-Mediated Tissue Injury in Non-human Primate Models of Viral Infections. Front Immunol 2018;9:2862. [PMID: 30568659 DOI: 10.3389/fimmu.2018.02862] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
32 Abdel-aal FA, Rageh AH, Said MI, Saleh GA. ε-MnO2-modified graphite electrode as a novel electrochemical sensor for the ultrasensitive detection of the newly FDA approved Hepatitis C antiviral drug ledipasvir. Analytica Chimica Acta 2018;1038:29-40. [DOI: 10.1016/j.aca.2018.07.018] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 4.6] [Reference Citation Analysis]
33 Kerkar N, Vergani D. De novo autoimmune hepatitis –is this different in adults compared to children? Journal of Autoimmunity 2018;95:26-33. [DOI: 10.1016/j.jaut.2018.10.023] [Cited by in Crossref: 28] [Cited by in F6Publishing: 28] [Article Influence: 5.6] [Reference Citation Analysis]
34 Lu H. Site-specific protein-polymer conjugate micelles with dramatically enhanced pharmacology. Sci China Mater 2018;61:1627-1628. [DOI: 10.1007/s40843-018-9354-8] [Reference Citation Analysis]
35 Mui UN, Haley CT, Vangipuram R, Tyring SK. Human oncoviruses: Mucocutaneous manifestations, pathogenesis, therapeutics, and prevention: Hepatitis viruses, human T-cell leukemia viruses, herpesviruses, and Epstein-Barr virus. J Am Acad Dermatol 2019;81:23-41. [PMID: 30502415 DOI: 10.1016/j.jaad.2018.10.072] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
36 Loseva EV, Loginova NA, Sarkisova KY, Klodt PM, Narkevich VB, Kudrin VS. Behavioral Symptoms of Anxiety and Depression and Brain Monoamine Contents in Rats after Chronic Intranasal Administration of Interferon-α. Neurosci Behav Physi 2018;48:954-962. [DOI: 10.1007/s11055-018-0655-8] [Reference Citation Analysis]
37 Seth D, Kamat D. Drug Allergy. Pediatr Ann 2018;47:e419-25. [PMID: 30308679 DOI: 10.3928/19382359-20180920-02] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
38 Yan Y, Liu S, Li M, Zhao Y, Shao X, Hang M, Bu X. Recombinant Newcastle disease virus expressing human IFN-λ1 (rL-hIFN-λ1)-induced apoptosis of A549 cells is connected to endoplasmic reticulum stress pathways. Thorac Cancer 2018;9:1437-52. [PMID: 30246439 DOI: 10.1111/1759-7714.12857] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
39 Araujo AM, Antunes MM, Mattos MS, Diniz AB, Alvarenga DM, Nakagaki BN, Carvalho É, Lacerda VAS, Carvalho-Gontijo R, Goulart J, Mafra K, Freitas-Lopes MA, Oliveira HMC, Dutra CM, David BA, Mendes Silva A, Quesniaux V, Ryffel B, Oliveira SC, Barber GN, Mansur DS, Cunha TM, Rezende RM, Oliveira AG, Menezes GB. Liver Immune Cells Release Type 1 Interferon Due to DNA Sensing and Amplify Liver Injury from Acetaminophen Overdose. Cells 2018;7:E88. [PMID: 30060463 DOI: 10.3390/cells7080088] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 3.4] [Reference Citation Analysis]
40 Zittoon RF, Madian YT, Alhennawi DEM, Nadeem HS. Cochlear Changes Caused by Peginterferon α-2b. J Interferon Cytokine Res 2018;38:311-6. [PMID: 30016180 DOI: 10.1089/jir.2018.0012] [Reference Citation Analysis]
41 Lee W, Kim M, Lee SH, Jung HG, Oh JW. Prophylactic efficacy of orally administered Bacillus poly-γ-glutamic acid, a non-LPS TLR4 ligand, against norovirus infection in mice. Sci Rep 2018;8:8667. [PMID: 29875467 DOI: 10.1038/s41598-018-26935-y] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 3.0] [Reference Citation Analysis]
42 Friedman A, Siewe N. Chronic hepatitis B virus and liver fibrosis: A mathematical model. PLoS One 2018;13:e0195037. [PMID: 29634771 DOI: 10.1371/journal.pone.0195037] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 1.4] [Reference Citation Analysis]
43 Li J, Huang S, Huang W, Wang W, Wen G, Gao L, Fu X, Wang M, Liang W, Kwan HY, Zhao X, Lv Z. Paeoniflorin ameliorates interferon-alpha-induced neuroinflammation and depressive-like behaviors in mice. Oncotarget 2017;8:8264-82. [PMID: 28030814 DOI: 10.18632/oncotarget.14160] [Cited by in Crossref: 25] [Cited by in F6Publishing: 27] [Article Influence: 5.0] [Reference Citation Analysis]
44 Suii H, Ozeki I, Tatsumi R, Yamaguchi M, Kimura M, Arakawa T, Nakajima T, Kuwata Y, Ohmura T, Hige S, Karino Y, Toyota J. Safety of Sofosbuvir and Ribavirin Combination Therapy in a Patient Who Developed Anemia due to Ribavirin. Case Reports Hepatol 2017;2017:8793895. [PMID: 29375917 DOI: 10.1155/2017/8793895] [Reference Citation Analysis]
45 Bakacs T, Safadi R, Kovesdi I. Post-infection viral superinfection technology could treat HBV and HCV patients with unmet needs. Hepatol Med Policy 2018;3:2. [PMID: 30288325 DOI: 10.1186/s41124-017-0028-x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
46 Pembroke T, Sebastiani G. Non-invasive Serum Markers of Fibrosis. Diagnostic Methods for Cirrhosis and Portal Hypertension 2018. [DOI: 10.1007/978-3-319-72628-1_5] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
47 Chung E, Park K, Kim JH, Han NI, Lee YS, Bae SH, Park CH. Development of bronchiolitis obliterans organizing pneumonia during standard treatment of hepatitis C with Peg-IFNα2b. Korean J Intern Med 2017;32:1098-100. [PMID: 28823117 DOI: 10.3904/kjim.2013.124] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
48 Retraction notice. Muscle Nerve 2017;55:766-766. [DOI: 10.1002/mus.21394] [Reference Citation Analysis]
49 Saghazadeh A, Rezaei N. Implications of Toll-like receptors in Ebola infection. Expert Opin Ther Targets 2017;21:415-25. [PMID: 28281905 DOI: 10.1080/14728222.2017.1299128] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
50 Yilmaz A, Ucmak F, Dönmezdil S, Kaya MC, Tekin R, Günes M, Arslan N, Bulut M. Somatosensory Amplification, Anxiety, and Depression in Patients With Hepatitis B: Impact on Functionality. Medicine (Baltimore) 2016;95:e3779. [PMID: 27227947 DOI: 10.1097/MD.0000000000003779] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
51 Baik SJ, Kim TH, Kim HI, Rhie JY. Myasthenia Crisis Induced by Pegylated-Interferon in Patient With Chronic Hepatitis C: A Case Report. Medicine (Baltimore) 2016;95:e3782. [PMID: 27227948 DOI: 10.1097/MD.0000000000003782] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
52 Arimoto KI, Löchte S, Stoner SA, Burkart C, Zhang Y, Miyauchi S, Wilmes S, Fan JB, Heinisch JJ, Li Z, Yan M, Pellegrini S, Colland F, Piehler J, Zhang DE. STAT2 is an essential adaptor in USP18-mediated suppression of type I interferon signaling. Nat Struct Mol Biol 2017;24:279-89. [PMID: 28165510 DOI: 10.1038/nsmb.3378] [Cited by in Crossref: 100] [Cited by in F6Publishing: 101] [Article Influence: 16.7] [Reference Citation Analysis]
53 Meanwell N. Direct-Acting Antiviral Agents for the Treatment of Hepatitis C Virus Infection. Comprehensive Medicinal Chemistry III 2017. [DOI: 10.1016/b978-0-12-409547-2.12406-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
54 Tu J, Li JJ, Shan ZJ, Zhai HL. Exploring the binding mechanism of Heteroaryldihydropyrimidines and Hepatitis B Virus capsid combined 3D-QSAR and molecular dynamics. Antiviral Research 2017;137:151-64. [DOI: 10.1016/j.antiviral.2016.11.026] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 2.8] [Reference Citation Analysis]
55 Günther C, He GW, Kremer AE, Murphy JM, Petrie EJ, Amann K, Vandenabeele P, Linkermann A, Poremba C, Schleicher U, Dewitz C, Krautwald S, Neurath MF, Becker C, Wirtz S. The pseudokinase MLKL mediates programmed hepatocellular necrosis independently of RIPK3 during hepatitis. J Clin Invest 2016;126:4346-60. [PMID: 27756058 DOI: 10.1172/JCI87545] [Cited by in Crossref: 105] [Cited by in F6Publishing: 109] [Article Influence: 15.0] [Reference Citation Analysis]
56 George J, Renn L, Verthelyi D, Roederer M, Rabin RL, Mattapallil JJ. Early treatment with reverse transcriptase inhibitors significantly suppresses peak plasma IFNα in vivo during acute simian immunodeficiency virus infection. Cell Immunol 2016;310:156-64. [PMID: 27622386 DOI: 10.1016/j.cellimm.2016.09.003] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
57 Malek-ahmadi P. Mood Disorders Associated with Interferon Treatment: Theoretical and Practical Considerations. Ann Pharmacother 2001;35:489-95. [DOI: 10.1345/aph.10172] [Cited by in Crossref: 29] [Cited by in F6Publishing: 29] [Article Influence: 4.1] [Reference Citation Analysis]
58 Song JS, Sohn JH, Jeong JY, Min JH, Choi WS, Kim OZ, Pyo JY. Repeated Panniculitis Induced by Pegylated Interferon Alpha 2a in a Patient with Chronic Hepatitis C. Korean J Gastroenterol 2016;67:272-6. [PMID: 27206440 DOI: 10.4166/kjg.2016.67.5.272] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
59 Gamal N, Andreone P. Safety and efficacy of once daily ledipasvir/sofosbuvir fixed-dose combination in patients with chronic hepatitis C. Expert Opin Drug Saf 2016;15:549-57. [PMID: 26899025 DOI: 10.1517/14740338.2016.1157163] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
60 Suprunenko T, Hofer MJ. The emerging role of interferon regulatory factor 9 in the antiviral host response and beyond. Cytokine Growth Factor Rev 2016;29:35-43. [PMID: 26987614 DOI: 10.1016/j.cytogfr.2016.03.002] [Cited by in Crossref: 27] [Cited by in F6Publishing: 22] [Article Influence: 3.9] [Reference Citation Analysis]
61 Kerkar N, Yanni G. ‘De novo’ and ‘recurrent’ autoimmune hepatitis after liver transplantation: A comprehensive review. Journal of Autoimmunity 2016;66:17-24. [DOI: 10.1016/j.jaut.2015.08.017] [Cited by in Crossref: 64] [Cited by in F6Publishing: 44] [Article Influence: 9.1] [Reference Citation Analysis]
62 Jackson WR, Campi EM, Hearn MTW. Closing Pandora's box: chemical products should be designed to preserve efficacy of function while reducing toxicity. Green Chem 2016;18:4140-4. [DOI: 10.1039/c6gc90073a] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
63 Baldo BA. Cytokines. Safety of Biologics Therapy 2016. [DOI: 10.1007/978-3-319-30472-4_5] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
64 Rehan HS, Chopra D, Yadav M, Wardhan N, Manak S, Siddiqui KM, Aslam M. Safety and efficacy of Qurse-e-istisqua in chronic hepatitis C infection: an exploratory study. Indian J Pharmacol 2015;47:72-9. [PMID: 25821315 DOI: 10.4103/0253-7613.150347] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
65 Singh A, Zaeri N, Ho IK. Onset of Celiac Disease after Treatment of Chronic Hepatitis C with Interferon Based Triple Therapy. Case Reports Hepatol 2015;2015:763497. [PMID: 26664772 DOI: 10.1155/2015/763497] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
66 Smyth D, Webster D. Hepatitis C: pay now or pay later? Future Virology 2015;10:1285-90. [DOI: 10.2217/fvl.15.104] [Reference Citation Analysis]
67 Suvak B, Dulger AC, Aykaç MC, Gonullu H, Gonullu E. Delta hepatitis-related thyroid disease: a unique phenomenon. Prz Gastroenterol 2015;10:169-72. [PMID: 26516384 DOI: 10.5114/pg.2015.49687] [Reference Citation Analysis]
68 Baldo BA. Side effects of cytokines approved for therapy. Drug Saf 2014;37:921-43. [PMID: 25270293 DOI: 10.1007/s40264-014-0226-z] [Cited by in Crossref: 91] [Cited by in F6Publishing: 77] [Article Influence: 11.4] [Reference Citation Analysis]
69 Kim KS, Hyun H, Yang JA, Lee MY, Kim H, Yun SH, Choi HS, Hahn SK. Bioimaging of Hyaluronate-Interferon α Conjugates Using a Non-Interfering Zwitterionic Fluorophore. Biomacromolecules 2015;16:3054-61. [PMID: 26258264 DOI: 10.1021/acs.biomac.5b00933] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 2.4] [Reference Citation Analysis]
70 Smyth DJ, Webster D, Barrett L, MacMillan M, McKnight L, Schweiger F. Transitioning to highly effective therapies for the treatment of chronic hepatitis C virus infection: a policy statement and implementation guideline. Can J Gastroenterol Hepatol 2014;28:529-34. [PMID: 25390613 DOI: 10.1155/2014/109046] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
71 Lim SG, Dan YY. A 2015 roadmap for the management of hepatitis C virus infections in Asia. Korean J Intern Med 2015;30:423-33. [PMID: 26161008 DOI: 10.3904/kjim.2015.30.4.423] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 2.3] [Reference Citation Analysis]
72 Rönsholt FF, Gerstoft J. Grazoprevir and elbasvir: a second-generation protease inhibitor and a second-generation NS5A inhibitor in a combination regimen for treatment of chronic hepatitis C. Future Virology 2015;10:691-8. [DOI: 10.2217/fvl.15.40] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
73 Porritt RA, Hertzog PJ. Dynamic control of type I IFN signalling by an integrated network of negative regulators. Trends in Immunology 2015;36:150-60. [DOI: 10.1016/j.it.2015.02.002] [Cited by in Crossref: 148] [Cited by in F6Publishing: 151] [Article Influence: 18.5] [Reference Citation Analysis]
74 Rycroft D, Sosabowski J, Coulstock E, Davies M, Morrey J, Friel S, Kelly F, Hamatake R, Ovečka M, Prince R, Goodall L, Sepp A, Walker A. Pharmacokinetic characteristics, pharmacodynamic effect and in vivo antiviral efficacy of liver-targeted interferon alpha. PLoS One 2015;10:e0117847. [PMID: 25689509 DOI: 10.1371/journal.pone.0117847] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
75 Cattie JE, Letendre SL, Woods SP, Barakat F, Perry W, Cherner M, Umlauf A, Franklin D, Heaton RK, Hassanein T. Persistent neurocognitive decline in a clinic sample of hepatitis C virus-infected persons receiving interferon and ribavirin treatment. J Neurovirol. 2014;20:561-570. [PMID: 25326107 DOI: 10.1007/s13365-014-0265-3] [Cited by in Crossref: 21] [Cited by in F6Publishing: 25] [Article Influence: 2.3] [Reference Citation Analysis]
76 Su K, Lai H, Yang H, Su W, Peng C, Chang JP, Chang H, Pariante CM. Omega-3 Fatty Acids in the Prevention of Interferon-Alpha-Induced Depression: Results from a Randomized, Controlled Trial. Biological Psychiatry 2014;76:559-66. [DOI: 10.1016/j.biopsych.2014.01.008] [Cited by in Crossref: 137] [Cited by in F6Publishing: 118] [Article Influence: 15.2] [Reference Citation Analysis]
77 Kashkouli MB, Shahrzad S. Intralesional Injection of Interferon-α2b in Orbital Eosinophilic Granuloma. Ophthalmic Plast Reconstr Surg 2016;32:e106-9. [PMID: 25226096 DOI: 10.1097/IOP.0000000000000289] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
78 Wedemeyer H. EASL Recognition Awardee for 2014: Prof. Geoff-Dusheiko. J Hepatol 2014;61:466-8. [PMID: 24972753 DOI: 10.1016/j.jhep.2014.05.036] [Reference Citation Analysis]
79 Shapiro PA, Sloan RP, Deochand C, Franceschi AM, Delorenzo C, Mann JJ, Parsey RV. Quantifying serotonin transporters by PET with [11C]-DASB before and after interferon-α treatment. Synapse 2014;68:548-55. [PMID: 25043294 DOI: 10.1002/syn.21766] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
80 Georgakopoulou EA, Scully C. Orofacial adverse effects of biological agents. J Investig Clin Dent 2015;6:252-60. [PMID: 24850782 DOI: 10.1111/jicd.12102] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 0.9] [Reference Citation Analysis]
81 Doherty L, Mutlu L, Sinclair D, Taylor H. Uterine fibroids: clinical manifestations and contemporary management. Reprod Sci 2014;21:1067-92. [PMID: 24819877 DOI: 10.1177/1933719114533728] [Cited by in Crossref: 51] [Cited by in F6Publishing: 55] [Article Influence: 5.7] [Reference Citation Analysis]
82 Fabrizi F, Aghemo A, Moroni G, Passerini P, D'Ambrosio R, Martin P, Messa P. De novo membrano-proliferative nephritis following interferon therapy for chronic hepatitis C (case study and literature review). Dig Dis Sci 2014;59:691-5. [PMID: 24318802 DOI: 10.1007/s10620-013-2959-4] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
83 Bhattacharya S, Katlinski KV, Reichert M, Takano S, Brice A, Zhao B, Yu Q, Zheng H, Carbone CJ, Katlinskaya YV, Leu NA, McCorkell KA, Srinivasan S, Girondo M, Rui H, May MJ, Avadhani NG, Rustgi AK, Fuchs SY. Triggering ubiquitination of IFNAR1 protects tissues from inflammatory injury. EMBO Mol Med 2014;6:384-97. [PMID: 24480543 DOI: 10.1002/emmm.201303236] [Cited by in Crossref: 45] [Cited by in F6Publishing: 45] [Article Influence: 5.0] [Reference Citation Analysis]
84 Sulkowski MS. Hepatitis C virus infection in HIV-infected patients. Curr Infect Dis Rep 2007;3:469-76. [PMID: 24395487 DOI: 10.1007/s11908-007-1004-1] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
85 Mashima H, Sakai T, Ohnishi H. The roles of interferon regulatory factors in pancreatic diseases. Journal of the Japan Pancreas Society 2014;29:23-31. [DOI: 10.2958/suizo.29.23] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
86 Simeon RL, Chen Z. A screen for genetic suppressor elements of hepatitis C virus identifies a supercharged protein inhibitor of viral replication. PLoS One 2013;8:e84022. [PMID: 24391867 DOI: 10.1371/journal.pone.0084022] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
87 Cao Y, Zhang R, Zhang W, Zhu C, Yu Y, Song Y, Wang Q, Bai L, Liu Y, Wu K, Wu J. IL-27, a cytokine, and IFN-λ1, a type III IFN, are coordinated to regulate virus replication through type I IFN. J Immunol 2014;192:691-703. [PMID: 24337382 DOI: 10.4049/jimmunol.1300252] [Cited by in Crossref: 34] [Cited by in F6Publishing: 35] [Article Influence: 3.4] [Reference Citation Analysis]
88 Campos‐de‐magalhães M, Eduardo Brandão‐mello C, Lúcia Elias Pires M, Cecília da Fonseca Salgado M, Barcelo de Brito S, José de Almeida A. Factor VIII and IX deficiencies related to acquired inhibitors in a patient with chronic hepatitis C virus infection receiving treatment with pegylated interferon plus ribavirin. Hematology 2013;16:80-5. [DOI: 10.1179/102453311x12902908412156] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.0] [Reference Citation Analysis]
89 Makris M, Dusheiko G. Hepatitis and Hemophilia. Viral Hepatitis 2013. [DOI: 10.1002/9781118637272.ch35] [Reference Citation Analysis]
90 Vera-Llonch M, Martin M, Aggarwal J, Donepudi M, Bayliss M, Goss T, Younossi Z. Health-related quality of life in genotype 1 treatment-naïve chronic hepatitis C patients receiving telaprevir combination treatment in the ADVANCE study. Aliment Pharmacol Ther 2013;38:124-33. [PMID: 23725204 DOI: 10.1111/apt.12354] [Cited by in Crossref: 37] [Cited by in F6Publishing: 27] [Article Influence: 3.7] [Reference Citation Analysis]
91 Coulstock E, Sosabowski J, Ovečka M, Prince R, Goodall L, Mudd C, Sepp A, Davies M, Foster J, Burnet J, Dunlevy G, Walker A. Liver-targeting of interferon-alpha with tissue-specific domain antibodies. PLoS One 2013;8:e57263. [PMID: 23451195 DOI: 10.1371/journal.pone.0057263] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 1.7] [Reference Citation Analysis]
92 Dusheiko G. Treatment of HBeAg positive chronic hepatitis B: interferon or nucleoside analogues. Liver Int 2013;33 Suppl 1:137-50. [PMID: 23286858 DOI: 10.1111/liv.12078] [Cited by in Crossref: 35] [Cited by in F6Publishing: 35] [Article Influence: 3.5] [Reference Citation Analysis]
93 Nair Kesavachandran C, Haamann F, Nienhaus A. Frequency of thyroid dysfunctions during interferon alpha treatment of single and combination therapy in hepatitis C virus-infected patients: a systematic review based analysis. PLoS One. 2013;8:e55364. [PMID: 23383326 DOI: 10.1371/journal.pone.0055364] [Cited by in Crossref: 19] [Cited by in F6Publishing: 22] [Article Influence: 1.9] [Reference Citation Analysis]
94 Dell'Osso B, Prati G, Palazzo MC, Rumi MG, Cavallaro F, Aghemo A, Colombo M, Altamura AC. Predictors of psychopathological outcome during peg-interferon and ribavirin therapy in patients with chronic HCV-correlated hepatitis. J Interferon Cytokine Res 2013;33:9-14. [PMID: 23276143 DOI: 10.1089/jir.2012.0060] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
95 Shi K, Cui F, Bi H, Jiang Y, Shi H, Song T. Metal ions guided self-assembly of therapeutic proteins for controllable release: from random to ordered aggregation. Pharm Res 2013;30:269-79. [PMID: 22975806 DOI: 10.1007/s11095-012-0871-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
96 Makowska Z, Heim MH. Interferon signaling in the liver during hepatitis C virus infection. Cytokine 2012;59:460-6. [DOI: 10.1016/j.cyto.2012.06.015] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 0.9] [Reference Citation Analysis]
97 George PM, Badiger R, Alazawi W, Foster GR, Mitchell JA. Pharmacology and therapeutic potential of interferons. Pharmacol Ther. 2012;135:44-53. [PMID: 22484806 DOI: 10.1016/j.pharmthera.2012.03.006] [Cited by in Crossref: 116] [Cited by in F6Publishing: 124] [Article Influence: 10.5] [Reference Citation Analysis]
98 Hillyer P, Mane VP, Schramm LM, Puig M, Verthelyi D, Chen A, Zhao Z, Navarro MB, Kirschman KD, Bykadi S, Jubin RG, Rabin RL. Expression profiles of human interferon-alpha and interferon-lambda subtypes are ligand- and cell-dependent. Immunol Cell Biol 2012;90:774-83. [PMID: 22249201 DOI: 10.1038/icb.2011.109] [Cited by in Crossref: 81] [Cited by in F6Publishing: 83] [Article Influence: 7.4] [Reference Citation Analysis]
99 de Knegt RJ, Bezemer G, Van Gool AR, Drenth JP, Hansen BE, Droogleever Fortuyn HA, Weegink CJ, Hengeveld MW, Janssen HL. Randomised clinical trial: escitalopram for the prevention of psychiatric adverse events during treatment with peginterferon-alfa-2a and ribavirin for chronic hepatitis C. Aliment Pharmacol Ther 2011;34:1306-17. [PMID: 21999489 DOI: 10.1111/j.1365-2036.2011.04867.x] [Cited by in Crossref: 29] [Cited by in F6Publishing: 33] [Article Influence: 2.4] [Reference Citation Analysis]
100 Aghemo A, Rumi MG, Monico S, Banderali M, Russo A, Ottaviani F, Vigano M, D'Ambrosio R, Colombo M. Ribavirin Impairs Salivary gland function During Combination Treatment With Pegylated Interferon Alfa-2a In HEpatitis C patients. Hepat Mon 2011;11:918-24. [PMID: 22308157 DOI: 10.5812/kowsar.1735143X.733] [Cited by in F6Publishing: 5] [Reference Citation Analysis]
101 Oh SY, Jones BE, Fernando SL. Interferon-α-related microscopic polyangiitis in a patient with chronic hepatitis C infection. Med J Aust 2011;195:385-6. [PMID: 21978341 DOI: 10.5694/mja11.10249] [Reference Citation Analysis]
102 Mendes-Corrêa MC, Bittar RS, Salmito N, Oiticica J. Pegylated interferon/ribavirin-associated sudden hearing loss in a patient with chronic hepatitis C in Brazil. Braz J Infect Dis 2011;15:87-9. [PMID: 21412597 DOI: 10.1016/s1413-8670(11)70147-7] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 0.3] [Reference Citation Analysis]
103 Li Q, Kawamura K, Okamoto S, Fujie H, Numasaki M, Namba M, Nagata M, Shimada H, Kobayashi H, Tagawa M. Adenoviruses-mediated transduction of human oesophageal carcinoma cells with the interferon-λ genes produced anti-tumour effects. Br J Cancer 2011;105:1302-12. [PMID: 21952623 DOI: 10.1038/bjc.2011.379] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 0.8] [Reference Citation Analysis]
104 Badrakalimuthu VR, Rumball D, Chawla A. Hepatitis C: a patient's journey from a psychiatrist's perspective. Adv psychiatr treat 2011;17:340-349. [DOI: 10.1192/apt.bp.109.007153] [Reference Citation Analysis]
105 Martinez-Camacho A, Khaoustov VI, Adam E, Lewis DE, Tavakoli-Tabasi S, Yoffe B. Lymphocytosis as a predictor of poor response to treatment of hepatitis C. Clin Res Hepatol Gastroenterol 2011;35:34-40. [PMID: 21185139 DOI: 10.1016/j.gcb.2010.08.008] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
106 Al-balbeesi AO. Significance of antithyroid antibodies and other auto-antibodies in Saudi patients with chronic urticaria. Possible parameters in predicting chronic over three years disease. Journal of the Saudi Society of Dermatology & Dermatologic Surgery 2011;15:47-51. [DOI: 10.1016/j.jssdds.2011.04.007] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
107 Popescu C, Arama V, Gliga S. Acute pericarditis due to pegylated interferon alpha therapy for chronic HCV hepatitis - case report. BMC Gastroenterol. 2011;11:30. [PMID: 21453456 DOI: 10.1186/1471-230x-11-30] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 1.2] [Reference Citation Analysis]
108 Ramsey SE, Engler PA, Stein MD, Brown RA, Cioe P, Kahler CW, Promrat K, Rose J, Anthony J, Solomon DA. Effect of CBT on Depressive Symptoms in Methadone Maintenance Patients Undergoing Treatment for Hepatitis C. J Addict Res Ther 2011;2:2-10. [PMID: 21743837 DOI: 10.4172/2155-6105.1000109] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 0.3] [Reference Citation Analysis]
109 Jong E, Oudhoff LA, Epskamp C, Wagener MN, van Duijn M, Fischer S, van Gorp EC. Predictors and treatment strategies of HIV-related fatigue in the combined antiretroviral therapy era. AIDS 2010;24:1387-405. [PMID: 20523204 DOI: 10.1097/QAD.0b013e328339d004] [Cited by in Crossref: 79] [Cited by in F6Publishing: 80] [Article Influence: 6.1] [Reference Citation Analysis]
110 Li Q, Kawamura K, Ma G, Iwata F, Numasaki M, Suzuki N, Shimada H, Tagawa M. Interferon-lambda induces G1 phase arrest or apoptosis in oesophageal carcinoma cells and produces anti-tumour effects in combination with anti-cancer agents. Eur J Cancer. 2010;46:180-190. [PMID: 19879751 DOI: 10.1016/j.ejca.2009.10.002] [Cited by in Crossref: 59] [Cited by in F6Publishing: 60] [Article Influence: 4.5] [Reference Citation Analysis]
111 Lotrich FE. Major depression during interferon-alpha treatment: vulnerability and prevention. Dialogues Clin Neurosci 2009;11:417-25. [PMID: 20135899 [PMID: 20135899 DOI: 10.31887/dcns.2009.11.4/felotrich] [Cited by in Crossref: 42] [Cited by in F6Publishing: 44] [Article Influence: 3.2] [Reference Citation Analysis]
112 Abushahba W, Balan M, Castaneda I, Yuan Y, Reuhl K, Raveche E, de la Torre A, Lasfar A, Kotenko SV. Antitumor activity of type I and type III interferons in BNL hepatoma model. Cancer Immunol Immunother 2010;59:1059-71. [PMID: 20217081 DOI: 10.1007/s00262-010-0831-3] [Cited by in Crossref: 78] [Cited by in F6Publishing: 74] [Article Influence: 6.0] [Reference Citation Analysis]
113 Heinze S, Egberts F, Rötzer S, Volkenandt M, Tilgen W, Linse R, Boettjer J, Vogt T, Spieth K, Eigentler T, Brockmeyer NH, Hinzpeter A, Hauschild A, Schaefer M. Depressive Mood Changes and Psychiatric Symptoms During 12-month Low-dose Interferon-α Treatment in Patients With Malignant Melanoma: Results From the Multicenter DeCOG Trial. Journal of Immunotherapy 2010;33:106-14. [DOI: 10.1097/cji.0b013e3181b8bdb9] [Cited by in Crossref: 27] [Cited by in F6Publishing: 30] [Article Influence: 2.1] [Reference Citation Analysis]
114 Wobrock T, Mihm U, Löhr C, Hofmann W, Sarrazin C, Zeuzem S, Falkai P. Cognition in hepatitis C patients treated with pegylated interferon. The World Journal of Biological Psychiatry 2009;10:819-26. [DOI: 10.1080/15622970701714362] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 0.9] [Reference Citation Analysis]
115 Sgorbini M, O'Brien L, Jackson D. Living with hepatitis C and treatment: the personal experiences of patients. J Clin Nurs 2009;18:2282-91. [PMID: 19583661 DOI: 10.1111/j.1365-2702.2009.02806.x] [Cited by in Crossref: 29] [Cited by in F6Publishing: 33] [Article Influence: 2.1] [Reference Citation Analysis]
116 Lechner J, Pfaller W. INTERFERON α2b INCREASES PARACELLULAR PERMEABILITY OF RENAL PROXIMAL TUBULAR LLC-PK 1 CELLS VIA A MITOGEN ACTIVATED PROTEIN KINASE SIGNALING PATHWAY. Renal Failure 2009;23:573-88. [DOI: 10.1081/jdi-100104739] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 0.9] [Reference Citation Analysis]
117 de Almeida AJ, Campos-de-Magalhães M, Antonietti CL, Brandão-Mello CE, da Silva ML, de Oliveira RV, do Espírito-Santo MP, Yoshida CF, Lampe E. Autoimmune thrombocytopenia related to chronic hepatitis C virus infection. Hematology 2009;14:49-58. [PMID: 19154665 DOI: 10.1179/102453309X385106] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.6] [Reference Citation Analysis]
118 Caraccio N, Cuccato S, Pratesi F, Dardano A, Ursino S, Chimenti D, Boldrini L, Materazzi G, Migliorini P, Monzani F. Effect of type I interferon(s) on cell viability and apoptosis in primary human thyrocyte cultures. Thyroid 2009;19:149-55. [PMID: 19191746 DOI: 10.1089/thy.2008.0290] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 1.1] [Reference Citation Analysis]
119 Kawaguchi T, Sumie S, Itou M, Taniguchi E, Matoba T, Sata M. Clinical benefits and cost-effectiveness of 17-year treatment with low-dose interferon-alpha 2b in a patient with chronic hepatitis C: a case report. Dig Dis Sci 2009;54:690-4. [PMID: 18661237 DOI: 10.1007/s10620-008-0397-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
120 Stübgen J. Interferon alpha and neuromuscular disorders. Journal of Neuroimmunology 2009;207:3-17. [DOI: 10.1016/j.jneuroim.2008.12.008] [Cited by in Crossref: 42] [Cited by in F6Publishing: 43] [Article Influence: 3.0] [Reference Citation Analysis]
121 Enright BP, Compton DR, Collins N, Davis T, Mcintyre BS. Comparative effects of interferon alpha-2b and pegylated interferon alpha-2b on menstrual cycles and ovarian hormones in cynomolgus monkeys. Birth Defect Res B 2009;86:29-39. [DOI: 10.1002/bdrb.20179] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
122 Soetekouw PM, Koopman M, Burger D, Tjan-Heijnen VC, De Mulder PH. Severe hyponatremia caused by hyperglycaemia due to interferon alpha therapy in advanced renal cell carcinoma. Acta Oncol 2009;48:154-6. [PMID: 19101828 DOI: 10.1080/02841860802047403] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
123 Shin MK, Kim TH, Ju K, Ha CY, Min HJ, Jung WT, Lee OJ. A case of sudden-onset hearing loss in a patient treated with peginterferon α-2b and ribavirin for chronic hepatitis C. Korean J Hepatol 2009;15:370. [DOI: 10.3350/kjhep.2009.15.3.370] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
124 Reed C, Stuver SO, Tumilty S, Nunes D, Murray JE, Graham CS, James Koziel M, Craven DE, Skolnik PR, Horsburgh CR Jr. Predictors of treatment for hepatitis C virus (HCV) infection in drug users. Subst Abus 2008;29:5-15. [PMID: 19042314 DOI: 10.1300/J465v29n01_02] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
125 Spirin NN, Kasatkin DS. The influences of cytokines as a possible substrate for the psychological effects of immunomodulation therapy in multiple sclerosis. Neurosci Behav Physi 2009;39:25-30. [DOI: 10.1007/s11055-008-9087-1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
126 Myint AM, Schwarz MJ, Steinbusch HW, Leonard BE. Neuropsychiatric disorders related to interferon and interleukins treatment. Metab Brain Dis 2009;24:55-68. [PMID: 19067144 DOI: 10.1007/s11011-008-9114-5] [Cited by in Crossref: 80] [Cited by in F6Publishing: 77] [Article Influence: 5.3] [Reference Citation Analysis]
127 Le V, Bader T, Fazili J. A case of hearing loss associated with pegylated interferon and ribavirin treatment ameliorated by prednisone. Nat Rev Gastroenterol Hepatol 2009;6:57-60. [DOI: 10.1038/ncpgasthep1317] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.5] [Reference Citation Analysis]
128 Pawelczyk T, Pawelczyk A, Strzelecki D, Rabe-jablonska J. Pegylated interferon α and ribavirin therapy may induce working memory disturbances in chronic hepatitis C patients. General Hospital Psychiatry 2008;30:501-8. [DOI: 10.1016/j.genhosppsych.2008.03.001] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 1.0] [Reference Citation Analysis]
129 Evon DM, Verma A, Simpson K, Galanko JA, Dougherty KA, Fried MW. Psychiatric symptoms during interferon treatment for hepatitis C: experiences from a tertiary care hepatology centre. Aliment Pharmacol Ther 2008;27:1071-80. [PMID: 18266996 DOI: 10.1111/j.1365-2036.2008.03640.x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 0.9] [Reference Citation Analysis]
130 Vartany E, Caldwell CA, Trow TK. Adult respiratory distress syndrome after treatment with pegylated interferon alpha-2a and ribavirin. Heart Lung 2008;37:153-6. [PMID: 18371508 DOI: 10.1016/j.hrtlng.2007.10.002] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
131 Chen P, Hwang Y, Lin CG, Wu Y, Wu LS. The genetic differences with whole genome linkage disequilibrium mapping between responder and non-responder in interferon-α and ribavirin combined therapy for chronic hepatitis C patients. Int J Immunogenet 2008;35:153-7. [DOI: 10.1111/j.1744-313x.2008.00754.x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
132 Latka MH, Hagan H, Kapadia F, Golub ET, Bonner S, Campbell JV, Coady MH, Garfein RS, Pu M, Thomas DL. A randomized intervention trial to reduce the lending of used injection equipment among injection drug users infected with hepatitis C. Am J Public Health. 2008;98:853-861. [PMID: 18382005 DOI: 10.2105/ajph.2007.113415] [Cited by in Crossref: 38] [Cited by in F6Publishing: 42] [Article Influence: 2.5] [Reference Citation Analysis]
133 de Beaurepaire R, Swiergiel AH, Dunn AJ. Neuroimmune Mediators: Are Cytokines Mediators of Depression? In: Licinio J, Wong M, editors. Biology of Depression. Wiley; 2005. pp. 557-81. [DOI: 10.1002/9783527619672.ch22] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
134 Myint AM, O'Mahony S, Kubera M, Kim YK, Kenny C, Kaim-Basta A, Steinbusch HW, Leonard BE. Role of paroxetine in interferon-alpha-induced immune and behavioural changes in male Wistar rats. J Psychopharmacol 2007;21:843-50. [PMID: 17984161 DOI: 10.1177/0269881107077165] [Cited by in Crossref: 23] [Cited by in F6Publishing: 27] [Article Influence: 1.5] [Reference Citation Analysis]
135 Cullen S, Chapman R. Sclerosing Cholangitis. Liver Immunology. [DOI: 10.1007/978-1-59745-518-3_20] [Reference Citation Analysis]
136 Hernandez L, Johnson TC, Naiyer AJ, Kryszak D, Ciaccio EJ, Min A, Bodenheimer HC Jr, Brown RS Jr, Fasano A, Green PH. Chronic hepatitis C virus and celiac disease, is there an association? Dig Dis Sci 2008;53:256-61. [PMID: 17549632 DOI: 10.1007/s10620-007-9851-z] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 1.1] [Reference Citation Analysis]
137 Le Corguillé M, Pochmalicki G, Eugène C. Complications cardiovasculaires de l’interféron-alpha. Gastroentérologie Clinique et Biologique 2007;31:1081-4. [DOI: 10.1016/s0399-8320(07)78339-2] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
138 Robaeys G, De Bie J, Wichers MC, Bruckers L, Nevens F, Michielsen P, Van Ranst M, Buntinx F. Early prediction of major depression in chronic hepatitis C patients during peg-interferon α-2b treatment by assessment of vegetative-depressive symptoms after four weeks. World J Gastroenterol 2007; 13(43): 5736-5740 [PMID: 17963300 DOI: 10.3748/wjg.v13.i43.5736] [Cited by in CrossRef: 14] [Cited by in F6Publishing: 16] [Article Influence: 0.9] [Reference Citation Analysis]
139 Elloumi H, Houissa F, Hadj NB, Gargouri D, Romani M, Kharrat J, Ghorbel A. Sudden hearing loss associated with peginterferon and ribavirin combination therapy during hepatitis C treatment. World J Gastroenterol 2007; 13(40): 5411-5412 [PMID: 17879419 DOI: 10.3748/wjg.v13.i40.5411] [Cited by in CrossRef: 12] [Cited by in F6Publishing: 14] [Article Influence: 0.8] [Reference Citation Analysis]
140 Kim YH, Han WS, Lee SJ, Oh SN, Choi DW, Byun KS, Yeon JE. [A case of vasculitis in chronic hepatitis C patient treated with pegylated interferon alpha-2a and ribavirin]. Korean J Hepatol 2007;13:419-22. [PMID: 17898559 DOI: 10.3350/kjhep.2007.13.3.419] [Reference Citation Analysis]
141 Kartal ED, Alpat SN, Ozgunes I, Usluer G. Adverse effects of high-dose interferon-alpha-2a treatment for chronic hepatitis B. Adv Ther 2007;24:963-71. [PMID: 18029321 DOI: 10.1007/BF02877700] [Cited by in Crossref: 9] [Cited by in F6Publishing: 13] [Article Influence: 0.6] [Reference Citation Analysis]
142 Szelényi J, Vizi E. Neuroimmune Correlates of Sleep in Depression: Role of Cytokines. Neuroimmunology of Sleep. [DOI: 10.1007/978-0-387-69146-6_18] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
143 Liu JH, Lin PW, Liu YL, Liao PY. Cervical spinal osteomyelitis with epidural abscess: a rare complication after interferon therapy following acute pyelonephritis. Nephrology (Carlton) 2007;12:418-9. [PMID: 17635760 DOI: 10.1111/j.1440-1797.2007.00808.x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
144 Aslan M, Nazligul Y, Aksoy N, Yilmaz N. A case of hyperthyroidy developing in "pegylated-interferon" therapy. Dig Dis Sci 2007;52:1194-6. [PMID: 17372828 DOI: 10.1007/s10620-006-9318-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
145 Lee S, Selva D, Huilgol SC, Goldberg RA, Leibovitch I. Pharmacological Treatments for Basal Cell Carcinoma: . Drugs 2007;67:915-34. [DOI: 10.2165/00003495-200767060-00007] [Cited by in Crossref: 20] [Cited by in F6Publishing: 23] [Article Influence: 1.3] [Reference Citation Analysis]
146 Buckwold VE, Lang W, Scribner C, Blanchett D, Alessi T, Langecker P. Safety pharmacology, toxicology and pharmacokinetic assessment of recombinant human omega-interferon produced from CHO-SS cells. Basic Clin Pharmacol Toxicol 2006;99:62-70. [PMID: 16867173 DOI: 10.1111/j.1742-7843.2006.pto_365.x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 0.6] [Reference Citation Analysis]
147 Doyle SE, Schreckhise H, Khuu-Duong K, Henderson K, Rosler R, Storey H, Yao L, Liu H, Barahmand-pour F, Sivakumar P, Chan C, Birks C, Foster D, Clegg CH, Wietzke-Braun P, Mihm S, Klucher KM. Interleukin-29 uses a type 1 interferon-like program to promote antiviral responses in human hepatocytes. Hepatology 2006;44:896-906. [PMID: 17006906 DOI: 10.1002/hep.21312] [Cited by in Crossref: 286] [Cited by in F6Publishing: 280] [Article Influence: 16.8] [Reference Citation Analysis]
148 Telio D, Sockalingam S, Stergiopoulos V. Persistent Psychosis After Treatment With Interferon Alfa: A Case Report. Journal of Clinical Psychopharmacology 2006;26:446-7. [DOI: 10.1097/01.jcp.0000227348.59912.5d] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 0.8] [Reference Citation Analysis]
149 Hayashi N, Takehara T. Antiviral therapy for chronic hepatitis C: past, present, and future. J Gastroenterol. 2006;41:17-27. [PMID: 16501853 DOI: 10.1007/s00535-005-1740-7] [Cited by in Crossref: 115] [Cited by in F6Publishing: 119] [Article Influence: 6.8] [Reference Citation Analysis]
150 Badra G, Waked I, Selmi C, Saleh SM, El-Shaarawy A, Lotfy M. Serum islet cell autoantibodies during interferon alpha treatment in patients with HCV-genotype 4 chronic hepatitis. Clin Dev Immunol 2006;13:11-5. [PMID: 16603440 DOI: 10.1080/17402520600557867] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
151 Sato A, Ohtsuki M, Hata M, Kobayashi E, Murakami T. Antitumor Activity of IFN-λ in Murine Tumor Models. J Immunol 2006;176:7686-94. [DOI: 10.4049/jimmunol.176.12.7686] [Cited by in Crossref: 139] [Cited by in F6Publishing: 144] [Article Influence: 8.2] [Reference Citation Analysis]
152 Cozzolongo R, Betterle C, Fabris P, Paola Albergoni M, Lanzilotta E, Manghisi OG. Onset of type 1 diabetes mellitus during peginterferon alpha-2b plus ribavirin treatment for chronic hepatitis C. Eur J Gastroenterol Hepatol 2006;18:689-92. [PMID: 16702861 DOI: 10.1097/00042737-200606000-00018] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 1.2] [Reference Citation Analysis]
153 Fekkes D, Bannink M, Kruit WH, Van Gool AR, Mulder PG, Sleijfer S, Eggermont AM, Stoter G. Influence of pegylated interferon-alpha therapy on plasma levels of citrulline and arginine in melanoma patients. Amino Acids 2007;32:121-6. [PMID: 16622596 DOI: 10.1007/s00726-006-0284-3] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 0.8] [Reference Citation Analysis]
154 Tsao CW, Lin YS, Cheng JT, Chang WW, Chen CL, Wu SR, Fan CW, Lo HY. Serotonin transporter mRNA expression is decreased by lamivudine and ribavirin and increased by interferon in immune cells. Scand J Immunol 2006;63:106-15. [PMID: 16476009 DOI: 10.1111/j.1365-3083.2005.01715.x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 0.6] [Reference Citation Analysis]
155 Okada AA. Immunomodulatory therapy for ocular inflammatory disease: a basic manual and review of the literature. Ocul Immunol Inflamm 2005;13:335-51. [PMID: 16419419 DOI: 10.1080/09273940590951034] [Cited by in Crossref: 50] [Cited by in F6Publishing: 43] [Article Influence: 2.9] [Reference Citation Analysis]
156 Lim SG, Wai C, Lee YM, Dan YY, Sutedja DS, Wee A, Suresh S, Wu YJ, Machin D, Lim CC, Fock KM, Koay E, Bowden S, Locarnini S, Ishaque SM. A Randomized, Placebo-Controlled Trial of Thymosin-α1 and Lymphoblastoid Interferon for Hbeag-Positive Chronic Hepatitis B. Antiviral Therapy 2006;11:245-254. [DOI: 10.1177/135965350601100206] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
157 Mehmet A, Yilmaz N, Zorludemir S, Güleryüz A, Acoskun B, Haciyakupoglu GM. Interferon-alpha2b may impair myelinization of rat optic nerve. Adv Ther 2006;23:23-32. [PMID: 16644604 DOI: 10.1007/BF02850343] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
158 Loomba R, Liang TJ. Novel Approaches to New Therapies for Hepatitis B Virus Infection. Antiviral Therapy 2006;11:1-15. [DOI: 10.1177/135965350601100113] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
159 Stadhouders P, Cooreman M. Wat kan de rol van de huisarts zijn bij een patiënt met een positieve hepatitis-C-serologie? Vademecum permanente nascholing huisartsen 2006. [DOI: 10.1007/978-90-313-8808-0_931] [Reference Citation Analysis]
160 Chang HJ, Choi EH, Kim IJ, Sim YS, Lee JH, Kim TH, Moon JW, Chun EM, Kim YK, Sung SH, Chang JH. Exacerbation of Sarcoidosis Following Interferon-alpha Therapy for Chronic Active Hepatitis C. Tuberc Respir Dis 2006;61:285. [DOI: 10.4046/trd.2006.61.3.285] [Reference Citation Analysis]
161 Iga D, Tomimatsu M, Endo H, Ohkawa S, Yamada O. Improvement of thrombocytopenia with disappearance of HCV RNA in patients treated by interferon-alpha therapy: possible etiology of HCV-associated immune thrombocytopenia. Eur J Haematol. 2005;75:417-423. [PMID: 16191092 DOI: 10.1111/j.1600-0609.2005.00524.x] [Cited by in Crossref: 31] [Cited by in F6Publishing: 39] [Article Influence: 1.7] [Reference Citation Analysis]
162 Crone C, Gabriel GM. Comprehensive review of hepatitis C for psychiatrists: risks, screening, diagnosis, treatment, and interferon-based therapy complications. J Psychiatr Pract. 2003;9:93-110. [PMID: 15985921 DOI: 10.1097/00131746-200303000-00002] [Cited by in Crossref: 42] [Cited by in F6Publishing: 47] [Article Influence: 2.3] [Reference Citation Analysis]
163 Reichenberg A, Gorman JM, Dieterich DT. Interferon-induced depression and cognitive impairment in hepatitis C virus patients: a 72 week prospective study. AIDS 2005;19 Suppl 3:S174-8. [PMID: 16251815 DOI: 10.1097/01.aids.0000192087.64432.ae] [Cited by in Crossref: 89] [Cited by in F6Publishing: 83] [Article Influence: 4.9] [Reference Citation Analysis]
164 Butnor KJ. Pulmonary Sarcoidosis Induced by Interferon-α Therapy. American Journal of Surgical Pathology 2005;29:976-9. [DOI: 10.1097/01.pas.0000160442.23523.0a] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 1.4] [Reference Citation Analysis]
165 Vignau J, Karila L, Costisella O, Canva V. Hépatite C, Interféron α et dépression : principales hypothèses physiopathologiques. L'Encéphale 2005;31:349-57. [DOI: 10.1016/s0013-7006(05)82400-5] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 0.8] [Reference Citation Analysis]
166 Cullen SN, Chapman RW. Review article: current management of primary sclerosing cholangitis. Aliment Pharmacol Ther 2005;21:933-48. [PMID: 15813829 DOI: 10.1111/j.1365-2036.2005.02407.x] [Cited by in Crossref: 57] [Cited by in F6Publishing: 54] [Article Influence: 3.2] [Reference Citation Analysis]
167 Fleming C, Tumilty S, Murray J, Nunes D. Challenges in the Treatment of Patients Coinfected with HIV and Hepatitis C Virus: Need for Team Care. CLIN INFECT DIS 2005;40:S349-54. [DOI: 10.1086/427452] [Cited by in Crossref: 41] [Cited by in F6Publishing: 43] [Article Influence: 2.3] [Reference Citation Analysis]
168 Doi F, Kakizaki S, Takagi H, Murakami M, Sohara N, Otsuka T, Abe T, Mori M. Long-term outcome of interferon-alpha-induced autoimmune thyroid disorders in chronic hepatitis C. Liver Int 2005;25:242-6. [PMID: 15780045 DOI: 10.1111/j.1478-3231.2005.01089.x] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 1.4] [Reference Citation Analysis]
169 Khalil A, Lucidarme D, Desurmont P, Hamdan-khalil R, Filoche B. Maladie de Crohn au cours du traitement de l’hépatite chronique C par interféron et ribavirine. Gastroentérologie Clinique et Biologique 2005;29:193-6. [DOI: 10.1016/s0399-8320(05)80736-5] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 1.2] [Reference Citation Analysis]
170 Kaygusuz I, Oztürk Kaygusuz T, Oztürk A, Kiliç SS, Karlidağ T, Keleş E, Yalçin S. Effects of interferon-alpha2b on hearing. Int J Audiol 2004;43:438-41. [PMID: 15643736 DOI: 10.1080/14992020400050055] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
171 Mulhall BP, Younossi Z. Impact of adherence on the outcome of antiviral therapy for chronic hepatitis C. J Clin Gastroenterol 2005;39:S23-7. [PMID: 15597024 DOI: 10.1097/01.mcg.0000145538.43865.72] [Cited by in Crossref: 37] [Cited by in F6Publishing: 32] [Article Influence: 2.1] [Reference Citation Analysis]
172 Homoncik M, Ferlitsch A, Ferenci P, Formann E, Jilma B, Gangl A, Panzer S, Peck-Radosavljevic M. Short- and long-term effects of therapy with interferon-alpha and pegylated interferon-alpha/ribavirin on platelet plug formation and von Willebrand factor release in patients with chronic hepatitis C. Aliment Pharmacol Ther 2005;21:49-55. [PMID: 15644045 DOI: 10.1111/j.1365-2036.2004.02305.x] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 0.9] [Reference Citation Analysis]
173 Khokhar O, Gange C, Clement S, Lewis J. Autoimmune hepatitis and thyroiditis associated with rifampin and pyrazinamide prophylaxis: an unusual reaction. Dig Dis Sci 2005;50:207-11. [PMID: 15712662 DOI: 10.1007/s10620-005-1302-0] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 0.7] [Reference Citation Analysis]
174 Bannink M, Kruit WH, Van Gool AR, Mulder PG, Sleijfer S, Eggermont AM, Stoter G, Fekkes D. Platelet MAO activity during treatment with pegylated interferon-alfa in melanoma patients. Prog Neuropsychopharmacol Biol Psychiatry 2005;29:109-14. [PMID: 15610952 DOI: 10.1016/j.pnpbp.2004.10.012] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
175 Durante-Mangoni E, Iardino P, Resse M, Cesaro G, Sica A, Farzati B, Ruggiero G, Adinolfi LE. Silent celiac disease in chronic hepatitis C: impact of interferon treatment on the disease onset and clinical outcome. J Clin Gastroenterol 2004;38:901-5. [PMID: 15492610 DOI: 10.1097/00004836-200411000-00014] [Cited by in Crossref: 42] [Cited by in F6Publishing: 40] [Article Influence: 2.2] [Reference Citation Analysis]
176 Van Gool AR, Fekkes D, Kruit WH, Mulder PG, Ten Hagen TL, Bannink M, Maes M, Eggermont AM. Serum amino acids, biopterin and neopterin during long-term immunotherapy with interferon-alpha in high-risk melanoma patients. Psychiatry Res 2003;119:125-32. [PMID: 12860366 DOI: 10.1016/s0165-1781(03)00113-6] [Cited by in Crossref: 27] [Cited by in F6Publishing: 31] [Article Influence: 1.4] [Reference Citation Analysis]
177 Matthews JD, Bini EJ. Epidemiology, Diagnosis, and Treatment of Chronic Hepatitis C. Journal of Pharmacy Practice 2004;17:229-238. [DOI: 10.1177/0897190004268869] [Reference Citation Analysis]
178 Monto A. Alcohol and hepatitis C: Implications for disease progression and treatment. Curr hepatitis rep 2004;3:105-111. [DOI: 10.1007/s11901-004-0017-6] [Reference Citation Analysis]
179 Brok J, Mellerup MT, Krogsgaard K, Gluud C; Cochrane Hepato-Biliary Group. Glucocorticosteroids for viral hepatitis C. Cochrane Database of Systematic Reviews. [DOI: 10.1002/14651858.cd002904.pub2] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.2] [Reference Citation Analysis]
180 Shin HY, Shin CH, Shin TY, Lee EJ, Kim HM. Effect of bojungikki-tang on lipopolysaccharide-induced cytokine production from peripheral blood mononuclear cells of chronic fatigue syndrome patients. Immunopharmacol Immunotoxicol 2003;25:491-501. [PMID: 14686792 DOI: 10.1081/iph-120026435] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 0.7] [Reference Citation Analysis]
181 Kainuma M, Sakai S, Sekiya N, Mantani N, Ogata N, Shimada Y, Terasawa K. The effects of a herbal medicine (Mao-to) in patients with chronic hepatitis C after injection of IFN-beta. Phytomedicine 2004;11:5-10. [PMID: 14971716 DOI: 10.1078/0944-7113-00344] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
182 Garbino J, Gerbase MW, Wunderli W, Kolarova L, Nicod LP, Rochat T, Kaiser L. Respiratory Viruses and Severe Lower Respiratory Tract Complications in Hospitalized Patients. Chest 2004;125:1033-9. [DOI: 10.1378/chest.125.3.1033] [Cited by in Crossref: 69] [Cited by in F6Publishing: 73] [Article Influence: 3.6] [Reference Citation Analysis]
183 Golstein PE, Delforge ML, Deviere J, Marcellin P. Reversible myopathy during successful treatment with pegylated interferon and ribavirin for acute hepatitis C. J Viral Hepat 2004;11:183-6. [PMID: 14996354 DOI: 10.1046/j.1365-2893.2003.00478.x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.2] [Reference Citation Analysis]
184 Gochee PA, Powell EE, Purdie DM, Pandeya N, Kelemen L, Shorthouse C, Jonsson JR, Kelly B. Association Between Apolipoprotein E ɛ4 and Neuropsychiatric Symptoms During Interferon α Treatment for Chronic Hepatitis C. Psychosomatics 2004;45:49-57. [DOI: 10.1176/appi.psy.45.1.49] [Cited by in Crossref: 27] [Cited by in F6Publishing: 31] [Article Influence: 1.4] [Reference Citation Analysis]
185 Shin H, An N, Cha Y, Shin E, Shin T, Baek S, Kim C, Lyu Y, Lee E, Kim H. Effect of Kuibitang on lipopolysaccharide-induced cytokine production in peripheral blood mononuclear cells of chronic fatigue syndrome patients. Journal of Ethnopharmacology 2004;90:253-9. [DOI: 10.1016/j.jep.2003.10.006] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
186 Lozano Arroyoa I, Ruiz Carriedob E. Interferón y depresión. A propósito de un caso. Atención Primaria 2004;34:442. [DOI: 10.1016/s0212-6567(04)78931-3] [Reference Citation Analysis]
187 Festi D, Sandri L, Mazzella G, Roda E, Sacco T, Staniscia T, Capodicasa S, Vestito A, Colecchia A. Safety of interferon β treatment for chronic HCV hepatitis. World J Gastroenterol 2004; 10(1): 12-16 [PMID: 14695760 DOI: 10.3748/wjg.v10.i1.12] [Cited by in CrossRef: 38] [Cited by in F6Publishing: 39] [Article Influence: 2.0] [Reference Citation Analysis]
188 Chapter 3 Health consequences of immunotoxic effects. Immunotoxicology of Drugs and Chemicals: an Experimental and Clinical Approach - Volume I: Principles and Methods of Immunotoxicology 2004. [DOI: 10.1016/s1873-9822(04)80004-2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
189 Shiffman ML, Vargas HE, Everson GT. Controversies in the management of hepatitis C virus infection after liver transplantation. Liver Transpl 2003;9:1129-44. [PMID: 14586872 DOI: 10.1053/jlts.2003.50261] [Cited by in Crossref: 25] [Cited by in F6Publishing: 20] [Article Influence: 1.3] [Reference Citation Analysis]
190 Borgia G, Reynaud L, Gentile I, Borrelli F, Cerini R, Ciampi R, Piazza M. Pernicious anemia during IFN-alpha treatment for chronic hepatitis C. J Interferon Cytokine Res 2003;23:11-2. [PMID: 12639294 DOI: 10.1089/10799900360520405] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 0.9] [Reference Citation Analysis]
191 Monto A. Alcohol and hepatitis C: Implications for disease progression and treatment. Curr hepatitis rep 2003;2:125-131. [DOI: 10.1007/s11901-003-0006-1] [Reference Citation Analysis]
192 Görür K, Kandemir O, Unal M, Ozcan C. The effect of recombinant interferon alpha treatment on hearing thresholds in patients with chronic viral hepatitis B. Auris Nasus Larynx. 2003;30:41-44. [PMID: 12589849 DOI: 10.1016/S0385-8146(02)00063-9] [Cited by in Crossref: 11] [Cited by in F6Publishing: 14] [Article Influence: 0.6] [Reference Citation Analysis]
193 Van Gool AR, Kruit WH, Engels FK, Stoter G, Bannink M, Eggermont AM. Neuropsychiatric side effects of interferon-alfa therapy. Pharm World Sci 2003;25:11-20. [PMID: 12661471 DOI: 10.1023/a:1022449613907] [Cited by in Crossref: 35] [Cited by in F6Publishing: 40] [Article Influence: 1.8] [Reference Citation Analysis]
194 Loftis JM, Hauser P. Comanagement of Depression and HCV Treatment. Psychiatric Annals 2003;33:385-91. [DOI: 10.3928/0048-5713-20030601-08] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 0.8] [Reference Citation Analysis]
195 Prummel MF, Laurberg P. Interferon-α and Autoimmune Thyroid Disease. Thyroid 2003;13:547-51. [DOI: 10.1089/105072503322238809] [Cited by in Crossref: 152] [Cited by in F6Publishing: 162] [Article Influence: 7.6] [Reference Citation Analysis]
196 Horikawa N, Yamazaki T, Izumi N, Uchihara M. Incidence and clinical course of major depression in patients with chronic hepatitis type C undergoing interferon-alpha therapy: a prospective study. Gen Hosp Psychiatry. 2003;25:34-38. [PMID: 12583926 DOI: 10.1016/s0163-8343(02)00239-6] [Cited by in Crossref: 101] [Cited by in F6Publishing: 108] [Article Influence: 5.1] [Reference Citation Analysis]
197 Rasenack J, Zeuzem S, Feinman SV, Heathcote EJ, Manns M, Yoshida EM, Swain MG, Gane E, Diago M, Revicki DA. Peginterferon alpha-2a (40kD) [Pegasys] improves HR-QOL outcomes compared with unmodified interferon alpha-2a [Roferon-A]: in patients with chronic hepatitis C. Pharmacoeconomics. 2003;21:341-349. [PMID: 12627987 DOI: 10.2165/00019053-200321050-00005] [Cited by in Crossref: 57] [Cited by in F6Publishing: 59] [Article Influence: 2.9] [Reference Citation Analysis]
198 Rubinowitz AN, Naidich DP, Alinsonorin C. Interferon-Induced Sarcoidosis: . Journal of Computer Assisted Tomography 2003;27:279-83. [DOI: 10.1097/00004728-200303000-00030] [Cited by in Crossref: 27] [Cited by in F6Publishing: 28] [Article Influence: 1.4] [Reference Citation Analysis]
199 Lee CA, Kessler CM, Varon D, Martinowitz U, Heim M, Dusheiko GM. Therapy for chronic hepatitis B and C infection in haemophilia. Haemophilia 1998;4:577-86. [DOI: 10.1046/j.1365-2516.1998.440577.x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
200 Sniezek JC, Francis TB. Inflammatory thyroid disorders. Otolaryngologic Clinics of North America 2003;36:55-71. [DOI: 10.1016/s0030-6665(02)00133-0] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
201 Ward DL, Bing-You RG. Autoimmune thyroid dysfunction induced by interferon-alpha treatment for chronic hepatitis C: screening and monitoring recommendations. Endocr Pract 2001;7:52-8. [PMID: 11250770 DOI: 10.4158/EP.7.1.52] [Cited by in Crossref: 27] [Cited by in F6Publishing: 29] [Article Influence: 1.4] [Reference Citation Analysis]
202 Sheppard P, Kindsvogel W, Xu W, Henderson K, Schlutsmeyer S, Whitmore TE, Kuestner R, Garrigues U, Birks C, Roraback J, Ostrander C, Dong D, Shin J, Presnell S, Fox B, Haldeman B, Cooper E, Taft D, Gilbert T, Grant FJ, Tackett M, Krivan W, McKnight G, Clegg C, Foster D, Klucher KM. IL-28, IL-29 and their class II cytokine receptor IL-28R. Nat Immunol 2003;4:63-8. [PMID: 12469119 DOI: 10.1038/ni873] [Cited by in Crossref: 1156] [Cited by in F6Publishing: 1199] [Article Influence: 55.0] [Reference Citation Analysis]
203 Clark CH, Mahoney JS, Clark DJ, Eriksen LR. Screening for depression in a hepatitis C population: the reliability and validity of the Center for Epidemiologic Studies Depression Scale (CES-D). J Adv Nurs 2002;40:361-9. [PMID: 12383188 DOI: 10.1046/j.1365-2648.2002.02378.x] [Cited by in Crossref: 61] [Cited by in F6Publishing: 65] [Article Influence: 2.9] [Reference Citation Analysis]
204 Fong T, Adkins RH, Govindarajan S, Post S, Waters RL. Prevalence of hepatitis C infection in a large urban hospital-based sample of individuals with spinal cord injury. Archives of Physical Medicine and Rehabilitation 2002;83:1620-3. [DOI: 10.1053/apmr.2002.00000] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
205 Moorman J. Challenges in the HIV patient coinfected with hepatitis C. Current Hepatitis Reports 2002;1:9-15. [DOI: 10.1007/s11901-002-0003-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.0] [Reference Citation Analysis]
206 Braun D, Caramalho I, Demengeot J. IFN-alpha/beta enhances BCR-dependent B cell responses. Int Immunol 2002;14:411-9. [PMID: 11934877 DOI: 10.1093/intimm/14.4.411] [Cited by in Crossref: 183] [Cited by in F6Publishing: 190] [Article Influence: 8.7] [Reference Citation Analysis]
207 Jacobs BP, Dennehy C, Ramirez G, Sapp J, Lawrence VA. Milk thistle for the treatment of liver disease. The American Journal of Medicine 2002;113:506-15. [DOI: 10.1016/s0002-9343(02)01244-5] [Cited by in Crossref: 156] [Cited by in F6Publishing: 163] [Article Influence: 7.4] [Reference Citation Analysis]
208 Fontana RJ, Schwartz SM, Gebremariam A, Lok AS, Moyer CA. Emotional Distress During Interferon-α-2B and Ribavirin Treatment of Chronic Hepatitis C. Psychosomatics 2002;43:378-85. [DOI: 10.1176/appi.psy.43.5.378] [Cited by in Crossref: 30] [Cited by in F6Publishing: 34] [Article Influence: 1.4] [Reference Citation Analysis]
209 Kumar KS, Russo MW, Borczuk AC, Brown M, Esposito SP, Lobritto SJ, Jacobson IM, Brown RS Jr. Significant pulmonary toxicity associated with interferon and ribavirin therapy for hepatitis C. Am J Gastroenterol 2002;97:2432-40. [PMID: 12358269 DOI: 10.1111/j.1572-0241.2002.05999.x] [Cited by in Crossref: 57] [Cited by in F6Publishing: 58] [Article Influence: 2.7] [Reference Citation Analysis]
210 Taki S. Type I interferons and autoimmunity: lessons from the clinic and from IRF-2-deficient mice. Cytokine & Growth Factor Reviews 2002;13:379-91. [DOI: 10.1016/s1359-6101(02)00023-0] [Cited by in Crossref: 33] [Cited by in F6Publishing: 36] [Article Influence: 1.6] [Reference Citation Analysis]
211 Sentjens RE, Weegink CJ, Beld MG, Cooreman MC, Reesink HW. Viral kinetics of hepatitis C virus RNA in patients with chronic hepatitis C treated with 18 MU of interferon alpha daily. Eur J Gastroenterol Hepatol 2002;14:833-40. [PMID: 12172402 DOI: 10.1097/00042737-200208000-00004] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 0.8] [Reference Citation Analysis]
212 Nawras A, Alsolaiman MM, Mehboob S, Bartholomew C, Maliakkal B. Systemic sarcoidosis presenting as a granulomatous tattoo reaction secondary to interferon-alpha treatment for chronic hepatitis C and review of the literature. Dig Dis Sci 2002;47:1627-31. [PMID: 12141827 DOI: 10.1023/a:1015843908536] [Cited by in Crossref: 50] [Cited by in F6Publishing: 50] [Article Influence: 2.4] [Reference Citation Analysis]
213 Willson RA. Nephrotoxicity of interferon alfa-ribavirin therapy for chronic hepatitis C. J Clin Gastroenterol 2002;35:89-92. [PMID: 12080234 DOI: 10.1097/00004836-200207000-00019] [Cited by in Crossref: 29] [Cited by in F6Publishing: 25] [Article Influence: 1.4] [Reference Citation Analysis]
214 Scott LJ, Perry CM. Interferon-alpha-2b plus ribavirin: a review of its use in the management of chronic hepatitis C. Drugs. 2002;62:507-556. [PMID: 11827565 DOI: 10.2165/00003495-200262030-00009] [Cited by in Crossref: 55] [Cited by in F6Publishing: 61] [Article Influence: 2.6] [Reference Citation Analysis]
215 Schaefer M, Engelbrechta MA, Gut O, Fiebich BL, Bauer J, Schmidt F, Grunze H, Lieb K. Interferon alpha (IFNα) and psychiatric syndromes. Progress in Neuro-Psychopharmacology and Biological Psychiatry 2002;26:731-46. [DOI: 10.1016/s0278-5846(01)00324-4] [Cited by in Crossref: 152] [Cited by in F6Publishing: 157] [Article Influence: 7.2] [Reference Citation Analysis]
216 Bernstein D, Kleinman L, Barker CM, Revicki DA, Green J. Relationship of health-related quality of life to treatment adherence and sustained response in chronic hepatitis C patients. Hepatology 2002;35:704-8. [PMID: 11870387 DOI: 10.1053/jhep.2002.31311] [Cited by in Crossref: 163] [Cited by in F6Publishing: 133] [Article Influence: 7.8] [Reference Citation Analysis]
217 De Meirleir K, De Becker P, Mcgregor N. RNase-L, Symptoms, Biochemistry of Fatigue and Pain, and Co-Morbid Disease. Chronic Fatigue Syndrome 2002. [DOI: 10.1201/9781420041002.ch7] [Reference Citation Analysis]
218 De Meirleir K, De Smet K, De Becker P, Mcgregor N. Current Advances in CFS Therapy. Chronic Fatigue Syndrome 2002. [DOI: 10.1201/9781420041002.ch9] [Reference Citation Analysis]
219 Perry CM, Jarvis B. Peginterferon-alpha-2a (40 kD): a review of its use in the management of chronic hepatitis C. Drugs. 2001;61:2263-2288. [PMID: 11772139 DOI: 10.2165/00003495-200161150-00013] [Cited by in Crossref: 75] [Cited by in F6Publishing: 81] [Article Influence: 3.6] [Reference Citation Analysis]
220 Melian EB, Plosker GL. Interferon alfacon-1: a review of its pharmacology and therapeutic efficacy in the treatment of chronic hepatitis C. Drugs 2001;61:1661-91. [PMID: 11577799 DOI: 10.2165/00003495-200161110-00009] [Cited by in Crossref: 47] [Cited by in F6Publishing: 51] [Article Influence: 2.2] [Reference Citation Analysis]
221 Chan J, O'Riordan K, Wiley TE. Amantadine's viral kinetics in chronic hepatitis C infection. Dig Dis Sci 2002;47:438-42. [PMID: 11855564 DOI: 10.1023/a:1013703013053] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 0.7] [Reference Citation Analysis]
222 Fontana RJ, Walsh J, Moyer CA, Lok AS, Webster S, Klein S. High-dose interferon alfa-2b and ribavirin in patients previously treated with interferon: results of a prospective, randomized, controlled trial. J Clin Gastroenterol 2002;34:177-82. [PMID: 11782615 DOI: 10.1097/00004836-200202000-00015] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
223 Chuntharapai A, Lai J, Huang X, Gibbs V, Kim KJ, Presta LG, Stewart TA. Characterization and humanization of a monoclonal antibody that neutralizes human leukocyte interferon: a candidate therapeutic for IDDM and SLE. Cytokine 2001;15:250-60. [PMID: 11594789 DOI: 10.1006/cyto.2001.0934] [Cited by in Crossref: 27] [Cited by in F6Publishing: 29] [Article Influence: 1.3] [Reference Citation Analysis]
224 Adamowicz-salach, Pawelec, Łoch, Zdziebłowska-pawińska, Brojer, Walewska-zielecka, Rokicka-milewska. Incidence and treatment of hepatitis C virus infection in children with haemophilia in Poland: HEPATITIS C IN CHILDREN WITH HAEMOPHILIA IN POLAND. Haemophilia 1999;5:436-40. [DOI: 10.1046/j.1365-2516.1999.00332.x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.4] [Reference Citation Analysis]
225 Hosoda S, Takimura H, Shibayama M, Kanamura H, Ikeda K, Kumada H. Psychiatric symptoms related to interferon therapy for chronic hepatitis C: Clinical features and prognosis. Psychiatry and Clinical Neurosciences 2001;54:565-72. [DOI: 10.1046/j.1440-1819.2000.00754.x] [Cited by in Crossref: 58] [Cited by in F6Publishing: 61] [Article Influence: 2.6] [Reference Citation Analysis]
226 Karim A, Ahmed S, Khan A, Steinberg H, Mattana J. Interstitial pneumonitis in a patient treated with alpha-interferon and ribavirin for hepatitis C infection. Am J Med Sci 2001;322:233-5. [PMID: 11678522 DOI: 10.1097/00000441-200110000-00015] [Cited by in Crossref: 26] [Cited by in F6Publishing: 29] [Article Influence: 1.2] [Reference Citation Analysis]
227 Gervais A, Boyer N, Marcellin P. Tolerability of treatments for viral hepatitis. Drug Saf 2001;24:375-84. [PMID: 11419564 DOI: 10.2165/00002018-200124050-00004] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 0.9] [Reference Citation Analysis]
228 Bogdanos DP, Choudhuri K, Vergani D. Molecular mimicry and autoimmune liver disease: virtuous intentions, malign consequences. Liver. 2001;21:225-232. [PMID: 11454184 DOI: 10.1034/j.1600-0676.2001.021004225.x] [Cited by in Crossref: 132] [Cited by in F6Publishing: 140] [Article Influence: 6.0] [Reference Citation Analysis]
229 Willson RA. Interferon alfa-induced pernicious anemia in chronic hepatitis C infection. J Clin Gastroenterol 2001;33:426-7. [PMID: 11606867 DOI: 10.1097/00004836-200111000-00021] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 0.5] [Reference Citation Analysis]
230 Sulkowski MS. Hepatitis C virus infection in HIV-infected patients. Curr Infect Dis Rep 2001;3:469-76. [DOI: 10.1007/bf03160472] [Cited by in Crossref: 29] [Cited by in F6Publishing: 18] [Article Influence: 1.3] [Reference Citation Analysis]
231 Malaguarnera M, Laurino A, Di Fazio I, Pistone G, Castorina M, Guccione N, Rampello L. Neuropsychiatric effects and type of IFN-alpha in chronic hepatitis C. J Interferon Cytokine Res. 2001;21:273-278. [PMID: 11429157 DOI: 10.1089/107999001300177457] [Cited by in Crossref: 47] [Cited by in F6Publishing: 51] [Article Influence: 2.1] [Reference Citation Analysis]
232 Willson RA. The benefit of long-term interferon alfa therapy for symptomatic mixed cryoglobulinemia (cutaneous vasculitis/membranoproliferative glomerulonephritis) associated with chronic hepatitis C infection. J Clin Gastroenterol 2001;33:137-40. [PMID: 11468441 DOI: 10.1097/00004836-200108000-00009] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.4] [Reference Citation Analysis]
233 Kurtzman AL, Govindarajan S, Vahle K, Jones JT, Heinrichs V, Patten PA. Advances in directed protein evolution by recursive genetic recombination: applications to therapeutic proteins. Current Opinion in Biotechnology 2001;12:361-70. [DOI: 10.1016/s0958-1669(00)00228-7] [Cited by in Crossref: 81] [Cited by in F6Publishing: 59] [Article Influence: 3.7] [Reference Citation Analysis]
234 Alric L, Duffaut M, Selves J, Sandre K, Mularczyck M, Izopet J, Desmorat H, Bureau C, Chaouche N, Dalbergue B, Vinel JP. Maintenance therapy with gradual reduction of the interferon dose over one year improves histological response in patients with chronic hepatitis C with biochemical response: results of a randomized trial. J Hepatol 2001;35:272-8. [PMID: 11580151 DOI: 10.1016/s0168-8278(01)00110-6] [Cited by in Crossref: 42] [Cited by in F6Publishing: 44] [Article Influence: 1.9] [Reference Citation Analysis]
235 Marinho RT, Johnson NW, Fatela NM, Serejo FS, Glória H, Raimundo MO, Velosa JF, Ramalho FJ, Moura MC. Oropharyngeal pemphigus in a patient with chronic hepatitis C during interferon alpha-2a therapy. Eur J Gastroenterol Hepatol 2001;13:869-72. [PMID: 11474319 DOI: 10.1097/00042737-200107000-00017] [Cited by in Crossref: 20] [Cited by in F6Publishing: 22] [Article Influence: 0.9] [Reference Citation Analysis]
236 Ohmoto K, Yamamoto S. Angioedema after interferon therapy for chronic hepatitis C. Am J Gastroenterol 2001;96:1311-2. [PMID: 11316204 DOI: 10.1111/j.1572-0241.2001.03735.x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 0.5] [Reference Citation Analysis]
237 Moorman JP. Issues in HIV/hepatitis C co-infection. Curr Infect Dis Rep 2001;3:131-6. [DOI: 10.1007/s11908-996-0035-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
238 Eibl N, Gschwantler M, Ferenci P, Eibl MM, Weiss W, Schernthaner G. Development of insulin-dependent diabetes mellitus in a patient with chronic hepatitis C during therapy with interferon-alpha. Eur J Gastroenterol Hepatol 2001;13:295-8. [PMID: 11293453 DOI: 10.1097/00042737-200103000-00015] [Cited by in Crossref: 35] [Cited by in F6Publishing: 35] [Article Influence: 1.6] [Reference Citation Analysis]
239 Waldrep TW, Summers KK, Chiliade PA. Coinfection with HIV and HCV: more questions than answers. Pharmacotherapy. 2000;20:1499-1507. [PMID: 11130222 DOI: 10.1592/phco.20.19.1499.34859] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.3] [Reference Citation Analysis]
240 Kleinman L, Zodet MW, Hakim Z, Aledort J, Barker C, Chan K, Krupp L, Revicki D. Psychometric evaluation of the fatigue severity scale for use in chronic hepatitis C. Qual Life Res 2000;9:499-508. [PMID: 11190005 DOI: 10.1023/a:1008960710415] [Cited by in Crossref: 128] [Cited by in F6Publishing: 133] [Article Influence: 5.8] [Reference Citation Analysis]
241 Queneau PE, Osaer F, Bronowicki JP, Monnot B, Thiefin G, Bettinger D, Carbillet JP, Raabe JJ, Fratte S, Minello-Franza A, Bresson-Hadni S, Miguet JP. Treatment of mild chronic hepatitis C with interferon alpha-2b: results of a multi-centre randomized study in 80 patients. Eur J Gastroenterol Hepatol 2001;13:143-7. [PMID: 11246613 DOI: 10.1097/00042737-200102000-00009] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
242 Kleinman L, Zodet MW, Hakim Z, Aledort J, Barker C, Chan K, Krupp L, Revicki D. Psychometric evaluation of the fatigue severity scale for use in chronic hepatitis C. Qual Life Res. 2000;9:499-508. [PMID: 11190005 DOI: 10.1023/a: 1008960710415] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
243 Hida S, Ogasawara K, Sato K, Abe M, Takayanagi H, Yokochi T, Sato T, Hirose S, Shirai T, Taki S, Taniguchi T. CD8(+) T cell-mediated skin disease in mice lacking IRF-2, the transcriptional attenuator of interferon-alpha/beta signaling. Immunity 2000;13:643-55. [PMID: 11114377 DOI: 10.1016/s1074-7613(00)00064-9] [Cited by in Crossref: 200] [Cited by in F6Publishing: 211] [Article Influence: 9.1] [Reference Citation Analysis]
244 Shirai T, Honjo Y, Takashima M, Takayanagi S, Chida K, Nakamura H. Effect of interferon-α on pulmonary function and airway responsiveness in patients with chronic hepatitis C. Allergology International 2001;50:331-5. [DOI: 10.1046/j.1440-1592.2001.00235.x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
245 Hu KQ, Vierling JM, Redeker AG. Viral, host and interferon-related factors modulating the effect of interferon therapy for hepatitis C virus infection. J Viral Hepat 2001;8:1-18. [PMID: 11155147 DOI: 10.1046/j.1365-2893.2001.00253.x] [Cited by in Crossref: 53] [Cited by in F6Publishing: 51] [Article Influence: 2.4] [Reference Citation Analysis]
246 Ho SB, Nguyen H, Tetrick LL, Opitz GA, Basara ML, Dieperink E. Influence of psychiatric diagnoses on interferon-alpha treatment for chronic hepatitis C in a veteran population. Am J Gastroenterol 2001;96:157-64. [PMID: 11197246 DOI: 10.1111/j.1572-0241.2001.03468.x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 35] [Article Influence: 0.4] [Reference Citation Analysis]
247 Kunkel EJ, Sung Kim J, Hann H, Oyesanmi O, Menefee LA, Field HL, Lartey PL, Myers RE. Depression in Korean Immigrants With Hepatitis B and Related Liver Diseases. Psychosomatics 2000;41:472-80. [DOI: 10.1176/appi.psy.41.6.472] [Cited by in Crossref: 41] [Cited by in F6Publishing: 43] [Article Influence: 1.8] [Reference Citation Analysis]
248 Schramm TM, Lawford BR, Cooksley WG, Macdonald GA. Sertraline treatment of interferon‐alfa‐induced depressive disorder. Medical Journal of Australia 2000;173:359-61. [DOI: 10.5694/j.1326-5377.2000.tb125687.x] [Cited by in Crossref: 80] [Cited by in F6Publishing: 87] [Article Influence: 3.5] [Reference Citation Analysis]
249 Wang Q, Miyakawa Y, Fox N, Kaushansky K. Interferon-α directly represses megakaryopoiesis by inhibiting thrombopoietin-induced signaling through induction of SOCS-1. Blood 2000;96:2093-9. [DOI: 10.1182/blood.v96.6.2093] [Cited by in Crossref: 103] [Cited by in F6Publishing: 102] [Article Influence: 4.5] [Reference Citation Analysis]
250 Wang Q, Miyakawa Y, Fox N, Kaushansky K. Interferon-α directly represses megakaryopoiesis by inhibiting thrombopoietin-induced signaling through induction of SOCS-1. Blood 2000;96:2093-9. [DOI: 10.1182/blood.v96.6.2093.h8002093_2093_2099] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.2] [Reference Citation Analysis]
251 García-Suárez J, Burgaleta C, Hernanz N, Albarran F, Tobaruela P, Alvarez-Mon M. HCV-associated thrombocytopenia: clinical characteristics and platelet response after recombinant alpha2b-interferon therapy. Br J Haematol. 2000;110:98-103. [PMID: 10930984 DOI: 10.1046/j.1365-2141.2000.02132.x] [Cited by in Crossref: 65] [Cited by in F6Publishing: 74] [Article Influence: 2.8] [Reference Citation Analysis]
252 Lövy MR, Starkebaum G. Rheumatic disorders associated with hepatitis C. Best Practice & Research Clinical Rheumatology 2000;14:535-57. [DOI: 10.1053/berh.2000.0092] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.3] [Reference Citation Analysis]
253 Benson L, Birkel A, Caldwell L, Stafford-fox V, Casarico B. Advances in the Treatment of Hepatitis C: Combination Antiviral Therapy With Interferon alfa-2b and Ribavirin. J Amer Acad Nurse Practitioners 2000;12:364-73. [DOI: 10.1111/j.1745-7599.2000.tb00197.x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.2] [Reference Citation Analysis]
254 Lau GK, Tsiang M, Hou J, Yuen S, Carman WF, Zhang L, Gibbs CS, Lam S. Combination therapy with lamivudine and famciclovir for chronic hepatitis B-infected Chinese patients: a viral dynamics study. Hepatology 2000;32:394-9. [PMID: 10915748 DOI: 10.1053/jhep.2000.9143] [Cited by in Crossref: 130] [Cited by in F6Publishing: 113] [Article Influence: 5.7] [Reference Citation Analysis]
255 Trask PC, Esper P, Riba M, Redman B. Psychiatric side effects of interferon therapy: prevalence, proposed mechanisms, and future directions. J Clin Oncol 2000;18:2316-26. [PMID: 10829053 DOI: 10.1200/JCO.2000.18.11.2316] [Cited by in Crossref: 130] [Cited by in F6Publishing: 136] [Article Influence: 5.7] [Reference Citation Analysis]
256 Dormann H, Krebs S, Muth-Selbach U, Brune K, Schuppan D, Hahn EG, Schneider HT. Rapid onset of hematotoxic effects after interferon alpha in hepatitis C. J Hepatol 2000;32:1041-2. [PMID: 10898329 DOI: 10.1016/s0168-8278(00)80113-0] [Cited by in Crossref: 13] [Cited by in F6Publishing: 17] [Article Influence: 0.6] [Reference Citation Analysis]
257 Zdilar D, Franco-Bronson K, Buchler N, Locala JA, Younossi ZM. Hepatitis C, interferon alfa, and depression. Hepatology 2000;31:1207-11. [PMID: 10827143 DOI: 10.1053/jhep.2000.7880] [Cited by in Crossref: 161] [Cited by in F6Publishing: 141] [Article Influence: 7.0] [Reference Citation Analysis]
258 Bogdanos DP, Mieli-Vergani G, Vergani D. Virus, liver and autoimmunity. Dig Liver Dis 2000;32:440-6. [PMID: 11030191 DOI: 10.1016/s1590-8658(00)80266-2] [Cited by in Crossref: 58] [Cited by in F6Publishing: 56] [Article Influence: 2.5] [Reference Citation Analysis]
259 Chutaputti A. Adverse effects and other safety aspects of the hepatitis C antivirals. J Gastroenterol Hepatol 2000;15 Suppl:E156-63. [PMID: 10921400 DOI: 10.1046/j.1440-1746.2000.02114.x] [Cited by in Crossref: 44] [Cited by in F6Publishing: 40] [Article Influence: 1.9] [Reference Citation Analysis]
260 Ben-noun LL. Interferon Therapy in Liver Cirrhosis Type C. Journal of Pharmacy Technology 2000;16:81-88. [DOI: 10.1177/875512250001600303] [Reference Citation Analysis]
261 Sarbah SA, Younossi ZM. Hepatitis C: an update on the silent epidemic. J Clin Gastroenterol 2000;30:125-43. [PMID: 10730918 DOI: 10.1097/00004836-200003000-00005] [Cited by in Crossref: 91] [Cited by in F6Publishing: 88] [Article Influence: 4.0] [Reference Citation Analysis]
262 Fontana RJ, Israel J, LeClair P, Banner BF, Tortorelli K, Grace N, Levine RA, Fiarman G, Thiim M, Tavill AS, Bonkovsky HL. Iron reduction before and during interferon therapy of chronic hepatitis C: results of a multicenter, randomized, controlled trial. Hepatology 2000;31:730-6. [PMID: 10706565 DOI: 10.1002/hep.510310325] [Cited by in Crossref: 116] [Cited by in F6Publishing: 102] [Article Influence: 5.0] [Reference Citation Analysis]
263 Shinzawa H, Yoshida Y, Masamune O, Toyota T, Takahashi T, Kasukawa R, Sudo T, Ishikawa K, Komatsu M, Ishii M, Takagi T, Hisamichi S, Sato S, Ichida H. Analysis of biochemical and virological efficacy of human lymphoblastoid interferon (IFN) in patients with compensated type C liver cirrhosis: comparative study between increase in individual IFN dose and prolonging of treatment period, using a multicenter randomized controlled trial. Dig Dis Sci 2000;45:575-80. [PMID: 10749335 DOI: 10.1023/a:1005409627192] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.0] [Reference Citation Analysis]
264 Treadwell JR, Kearney D, Davila M. Health profile preferences of hepatitis C patients. Dig Dis Sci 2000;45:345-50. [PMID: 10711449 DOI: 10.1023/a:1005420828332] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.3] [Reference Citation Analysis]
265 Epstein MP, Knox T. Current views on hepatitis C virus infection. Curr Infect Dis Rep 2000;2:55-60. [DOI: 10.1007/s11908-000-0088-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
266 García-Escaño MD, Andrade RJ, González-Santos P. [Interferon and plasma lipids]. Med Clin (Barc) 2000;114:74-6. [PMID: 10702954 DOI: 10.1016/s0025-7753(00)71192-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.0] [Reference Citation Analysis]
267 Watson KJR. Preventing hepatitis C virus transmission in Australians who inject drugs: Prevention, through harm minimisation, remains preferable to cure. Medical Journal of Australia 2000;172:55-6. [DOI: 10.5694/j.1326-5377.2000.tb139198.x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.1] [Reference Citation Analysis]
268 Steinkühler C, Koch U, De Francesco R, Pessi A. The Proteinases Encoded by Hepatitis C Virus as Therapeutic Targets. In: von der Helm K, Korant BD, Cheronis JC, editors. Proteases as Targets for Therapy. Berlin: Springer Berlin Heidelberg; 2000. pp. 75-94. [DOI: 10.1007/978-3-642-57092-6_5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.0] [Reference Citation Analysis]
269 Llovet JM, Sala M, Castells L, Suarez Y, Vilana R, Bianchi L, Ayuso C, Vargas V, Rodés J, Bruix J. Randomized controlled trial of interferon treatment for advanced hepatocellular carcinoma. Hepatology 2000;31:54-8. [PMID: 10613728 DOI: 10.1002/hep.510310111] [Cited by in Crossref: 187] [Cited by in F6Publishing: 179] [Article Influence: 8.1] [Reference Citation Analysis]
270 Mchutchison JG, Hoofnagle JH. II Therapy of chronic hepatitis C. Hepatitis C. Elsevier; 2000. pp. 203-39. [DOI: 10.1016/s1874-5326(00)80015-0] [Cited by in Crossref: 3] [Article Influence: 0.1] [Reference Citation Analysis]
271 Lo Iacono O, Fernández Bermejo M. Tratamiento de las hepatitis crónicas víricas. Medicine - Programa de Formación Médica Continuada Acreditado 2000;8:686-692. [DOI: 10.1016/s0304-5412(00)70130-2] [Reference Citation Analysis]
272 Van Gool AR, Kruit WH, Cornelissen JJ, Berk L, Eggermont AM, Bannink M. Management of psychiatric adverse events with immunotherapy with interferon-alfa. Acta Neuropsychiatr 1999;11:120-4. [PMID: 26976539 DOI: 10.1017/S0924270800035857] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.3] [Reference Citation Analysis]
273 Broussolle C, Steineur MP, Bailly F, Zoulim F, Trépo C. [Hepatitis C virus infection and thyroid diseases]. Rev Med Interne. 1999;20:766-773. [PMID: 10522298 DOI: 10.1016/s0248-8663(00)88683-x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 0.5] [Reference Citation Analysis]
274 Ahmed A, Keeffe EB. Overview of interferon therapy for chronic hepatitis C. Clin Liver Dis 1999;3:757-73. [PMID: 11291249 DOI: 10.1016/s1089-3261(05)70237-3] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.4] [Reference Citation Analysis]
275 Clark CH, Ghalib RH. Hepatitis C: Role of the Advanced Practice Nurse: . AACN Clinical Issues: Advanced Practice in Acute and Critical Care 1999;10:455-63. [DOI: 10.1097/00044067-199911000-00005] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.3] [Reference Citation Analysis]
276 Dumoulin FL, Leifeld L, Sauerbruch T, Spengler U. Autoimmunity induced by interferon-alpha therapy for chronic viral hepatitis. Biomed Pharmacother. 1999;53:242-254. [PMID: 10424246 DOI: 10.1016/s0753-3322(99)80095-x] [Cited by in Crossref: 70] [Cited by in F6Publishing: 65] [Article Influence: 2.9] [Reference Citation Analysis]
277 Lock G, Reng CM, Graeb C, Anthuber M, Wiedmann KH. Interferon-induced hepatic failure in a patient with hepatitis C. Am J Gastroenterol 1999;94:2570-1. [PMID: 10484034 DOI: 10.1111/j.1572-0241.1999.02570.x] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 0.7] [Reference Citation Analysis]
278 Karni A, Abramsky O. Association of MS with thyroid disorders. Neurology 1999;53:883-883. [DOI: 10.1212/wnl.53.4.883] [Cited by in Crossref: 55] [Cited by in F6Publishing: 56] [Article Influence: 2.3] [Reference Citation Analysis]
279 Chang CJ, Chen TT, Cox BW, Dawes GN, Stemmer WP, Punnonen J, Patten PA. Evolution of a cytokine using DNA family shuffling. Nat Biotechnol 1999;17:793-7. [DOI: 10.1038/11737] [Cited by in Crossref: 88] [Cited by in F6Publishing: 95] [Article Influence: 3.7] [Reference Citation Analysis]
280 Horsmans Y. [New therapeutic possibilities in the treatment of hepatitis B]. Arch Pediatr 1999;6 Suppl 2:180s-2s. [PMID: 10370473 DOI: 10.1016/s0929-693x(99)80405-9] [Reference Citation Analysis]
281 Lechner J, Krall M, Netzer A, Radmayr C, Ryan MP, Pfaller W. Effects of interferon alpha-2b on barrier function and junctional complexes of renal proximal tubular LLC-PK1 cells. Kidney Int. 1999;55:2178-2191. [PMID: 10354267 DOI: 10.1046/j.1523-1755.1999.00487.x] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 1.0] [Reference Citation Analysis]
282 Chemello L, Cavalletto L, Bernardinello E, Boccato S, Casarin P, Cavinato F, Urban F, Pontisso P, Cecchetto A, Gatta A, Alberti A. Comparison of thrice weekly vs daily human leucocyte interferon-alpha therapy for chronic hepatitis C. TVVH Study Group. J Viral Hepat 1999;6:321-7. [PMID: 10607247 DOI: 10.1046/j.1365-2893.1999.00165.x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.3] [Reference Citation Analysis]
283 Su L, David M. Inhibition of B Cell Receptor-Mediated Apoptosis by IFN. The Journal of Immunology 1999;162:6317-6321. [DOI: 10.4049/jimmunol.162.11.6317] [Cited by in Crossref: 1] [Article Influence: 0.0] [Reference Citation Analysis]
284 Saab S, Martin P. Hemolytic anemia and the treatment of chronic hepatitis C. J Clin Gastroenterol 1999;28:289-90. [PMID: 10372922 DOI: 10.1097/00004836-199906000-00001] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 0.4] [Reference Citation Analysis]
285 Kakizaki S, Takagi H, Murakami M, Takayama H, Mori M. HLA antigens in patients with interferon-alpha-induced autoimmune thyroid disorders in chronic hepatitis C. J Hepatol 1999;30:794-800. [PMID: 10365804 DOI: 10.1016/s0168-8278(99)80131-7] [Cited by in Crossref: 46] [Cited by in F6Publishing: 55] [Article Influence: 1.9] [Reference Citation Analysis]
286 Ahmed A, Keeffe EB. Treatment strategies for chronic hepatitis C: update since the 1997 National Institutes of Health Consensus Development Conference. J Gastroenterol Hepatol 1999;14 Suppl:S12-8. [PMID: 10382632 DOI: 10.1046/j.1440-1746.1999.01875.x] [Cited by in Crossref: 27] [Cited by in F6Publishing: 30] [Article Influence: 1.1] [Reference Citation Analysis]
287 Cadoni G, Marinelli L, De Santis A, Romito A, Manna R, Ottaviani F. Sudden hearing loss in a patient hepatitis C virus (HCV) positive on therapy with alpha-interferon: a possible autoimmune-microvascular pathogenesis. J Laryngol Otol 1998;112:962-3. [PMID: 10211222 DOI: 10.1017/s0022215100142197] [Cited by in Crossref: 28] [Cited by in F6Publishing: 29] [Article Influence: 1.2] [Reference Citation Analysis]
288 Okada AA, Keino H, Fukai T, Sakai J, Usui M, Mizuguchi J. Effect of type I interferon on experimental autoimmune uveoretinitis in rats. Ocul Immunol Inflamm 1998;6:215-26. [PMID: 9924918 DOI: 10.1076/ocii.6.4.215.4024] [Cited by in Crossref: 23] [Cited by in F6Publishing: 29] [Article Influence: 1.0] [Reference Citation Analysis]
289 Wada M, Miyoshi T, Fujimoto M, Kamimoto H, Kinugasa A, Sawada K, Shimoyama T. Serum Levels of Thyroid-Stimulating Hormone Receptor Antibodies during IFN-alpha2a Treatment of Chronic Hepatitis C. Journal of Interferon & Cytokine Research 1999;19:85-8. [DOI: 10.1089/107999099314450] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
290 Plotnikoff N, Faith R, Murgo A. Neuropeptides, Cytokines, and Cancer - Interrelationships. Cytokines 1998. [DOI: 10.1201/9781420048193.ch10] [Reference Citation Analysis]
291 McDiarmid SV, Conrad A, Ament ME, Vargas J, Martin MG, Goss JA, Busuttil RW. De novo hepatitis C in children after liver transplantation. Transplantation. 1998;66:311-318. [PMID: 9721798 DOI: 10.1097/00007890-199808150-00006] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 0.6] [Reference Citation Analysis]
292 Hoffmann RM, Ott S, Parhofer KG, Bartl R, Pape GR. Interferon-alpha-induced agranulocytosis in a patient on long-term clozapine therapy. J Hepatol 1998;29:170. [PMID: 9696507 DOI: 10.1016/s0168-8278(98)80193-1] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 0.5] [Reference Citation Analysis]
293 Hoffmann RM, Jung MC, Motz R, Gössl C, Emslander HP, Zachoval R, Pape GR. Sarcoidosis associated with interferon-alpha therapy for chronic hepatitis C. J Hepatol 1998;28:1058-63. [PMID: 9672184 DOI: 10.1016/s0168-8278(98)80357-7] [Cited by in Crossref: 97] [Cited by in F6Publishing: 106] [Article Influence: 3.9] [Reference Citation Analysis]
294 Naoumov NV, Rossol S. Studies of interleukin-12 in chronic hepatitis B virus infection. J Viral Hepat 1997;4 Suppl 2:87-91. [PMID: 9429215 DOI: 10.1111/j.1365-2893.1997.tb00185.x] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 0.5] [Reference Citation Analysis]
295 Davis GL. Treatment of acute and chronic hepatitis C. Clin Liver Dis 1997;1:615-30. [PMID: 15560062 DOI: 10.1016/s1089-3261(05)70325-1] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 0.4] [Reference Citation Analysis]
296 [DOI: 10.1101/2020.06.08.141077] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Reference Citation Analysis]